Effects of Ingesting a Preworkout Supplement for 7 Days on Exercise Performance and Cognitive Function by Koozehchian, Majid Surena
EFFECTS OF INGESTING A PREWORKOUT SUPPLEMENT FOR 7 
DAYS ON EXERCISE PERFORMANCE AND COGNITIVE FUNCTION 
A Dissertation 
by 
MAJID SURENA KOOZEHCHIAN 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
Chair of Committee,  
Committee Members, 
Head of Department, 
Richard B. Kreider  
Chris R Woodman  
John M Lawler  
Susanne M. Talcott 
Richard B. Kreider 
May 2017 
Major Subject: Kinesiology 
     Copyright 2017 Majid Koozehchian 
 ii 
 
 
ABSTRACT  
 
We examined the effects of ingesting two pre-workout supplements (PWS) on 
cognitive function, perceived readiness, and exercise performance related parameters. 
Resistance-trained participants (N=19) were randomized to a double-blind, cross-over 
(7-day washout), placebo-controlled study supplemented with: (1) Placebo (PLA); (2) 
PWS (caffeine, creatine nitrate in a 2:1 ratio as a salt, β-alanine, arginine alpha-
ketoglutarate, ascorbic acid, N-acetyl tyrosine, Mucuna pruriens), and (3) PWS150 at 
~150% of the PWS dose. Participants were tested on hemodynamic responses, resting 
energy expenditure, cognitive function (Stroop Color-Word test), self-perceived 
readiness, three sets of bench and leg press at 70% of 1RM, a 30-sec anaerobic capacity 
test, side effect questionnaires, and donated blood samples before and/or after acute 
ingestion, then after 7 days of supplementation. Data were analyzed by GLM and 
presented as mean (SD) or mean change (95% CI). Significant improvements in Stroop 
Word testing were observed for PWS (6.57 counts, 95% CI 1.36, 11.8) and PWS150 
(11.5 counts, 95% CI 6.26, 16.6), but not PLA (1.31 counts, 95% CI -3.89, 6.52). 
Significant changes in Stroop Color testing were observed for PWS150 (8.1 counts, 95% 
CI 4.52, 11.6) and PLA (4.47 counts, 95% CI 0.89, 8.05), but not PWS (2.31 counts, 
95% CI -1.26, 5.89). Similar results were observed for Word-Color. When all domains 
were summed, PWS150 (27.4 counts, 95% CI, 16.1, 38.7) and PWS (12.3 counts, 95% 
CI, 1.0, 23.5) showed significant improvements, but not PLA (11.3 counts, 95% CI, -
.002, 22.5). We observed significant improvements in Wingate mean power for PWS150 
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(26.0 watt, 95 CI, 1.85, 50.3), but not PWS (-3.83 watt, 95 CI, -28.7, 21.0) and PLA 
(8.88 watt, 95 CI, -17.5, 35.2). No significant or adverse changes were observed for 
hemodynamic, thermogenic, and hematologic variables.  The PW150 demonstrated 
consistent improvements in cognitive function; yet was unmatched by changes in self-
perceived readiness or other measured parameters associated with exercise performance. 
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CHAPTER I  
INTRODUCTION AND RATIONALE 
Background 
Nutritional supplement intended for consumption before exercise may improve 
cognitive function and/or resistance exercise performance [1]. Consequently, several 
nutritional strategies such as energy drinks (ED) and preworkout supplement (PWS) 
developed to optimize nutrient delivery prior to exercise [2, 3]. This includes providing 
carbohydrate and several ergogenic nutrients to increase energy availability [4], and/or 
positively affect exercise capacity [5]. The composition of PWS vary widely, but the 
principle ingredients consistently include carbohydrates, electrolytes, and caffeine [1]. In 
addition, some PWS also contain other nutrients like nitrates which cause some exercise 
benefits such as reducing blood pressure (BP) and oxygen cost of submaximal exercise 
[6]. Several studies indicate that caffeinated supplements improve performance which 
has increased interest in caffeinated sport drinks [7-9]. There are some other evidence 
showing that ingesting caffeine-containing supplements prior to exercise improves 
memory, concentration, and complex reaction times in athletes [10-14]. Caffeine could 
permit athletes to train at a greater power output and/or to train longer. It has also been 
shown to increase speed and/or power output in simulated race conditions [15]. Caffeine 
acts on the central nervous system as an adenosine antagonist, but may also have an 
effect on substrate metabolism and neuromuscular function [16].  
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Numerous studies have examined the safety and efficacy of individual PWS’s 
such as creatine monohydrate [17], carbohydrate [18], protein [19], and amino acids [20] 
as well as whether adding potentially ergogenic nutrients to PWS’s may promote 
additive benefits [1]. For example, several studies have reported that ingestion of PWS’s 
can cause improvements in exercise capacity [21], body composition [22], muscle mass 
and strength [23], reaction time [24], and/or subjective feelings of focus and energy [25].  
While many ingredients used in PWS studies have had their safety and efficacy 
assessed, the interactions when combined are less understood. The present study 
examined the thermogenic, hemodynamic, and ergogenic effects of acute ingestion or 7 
days of PWS supplementation (two doses) in healthy individuals. Thermogenic means 
tending to produce heat, and the term is commonly applied to nutrients which increase 
heat through metabolic stimulation [26]. Hemodynamics is the dynamics of blood flow 
such as heart rate and blood pressure [27]. Ergogenic means able to improve work or 
performance [28]. The formulation of the two doses of PWS and a PLA which was used 
for a 7 day duration contained: (1) Flavored dextrose PLA (12g); (2) PWS [β-alanine 
(3.2g), arginine α-ketoglutarate (2.0g), creatine nitrate (2.0g), ascorbic acid (500mg), N-
acetyl tyrosine (300mg), caffeine (300mg), tetramethyluric acid (10mg), Mucuna 
pruriens (1.0g), dextrose (2.6g)]; (3) PWS at ~150% dosage (PWS150), interspersed by 
7 day of washout period. Formulation decision was made by the supplement provider 
company based on previous studies and results from Texas A&M University. The 
formula that we used in the current study is a PWS formula so the results should be 
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immediate. If a supplement user does not see a result immediately or within 7 days, then 
the supplement is not effective.   
Several studies show that ingesting supplements containing caffeine, creatine, L-
arginine, and β-alanine prior to exercise can affect acute physical performance and/or 
cognitive function [21, 23, 24, 29, 30]. Caffeine is one of the most widely consumed 
ergogenic aids, with acute caffeine ingestion improving aerobic exercise endurance and 
reducing fatigue [31-33]. When ingested before exercise, caffeine (~3-6mg/kg) [16] has 
shown to improve exercise performance [34-36] and cognitive function [37, 38]. 
Plausible theories for the beneficial impact of caffeine include an increase in central 
nervous system activity [39, 40], enhancing calcium release and uptake to the 
sarcoplasmic reticulum [41], increasing plasma epinephrine concentrations [42], and 
functioning as an adenosine receptor antagonist [43, 44]. Caffeine is a receptor 
antagonist at all adenosine receptor subtypes. Antagonism at adenosine receptors 
stimulates the medullary vagal, vasomotor, and respiratory centers, which increases 
respiratory rate, reduces heart rate, and constricts blood vessels. In addition, adenosine 
receptor antagonism promotes neurotransmitter release (e.g., monoamines and 
acetylcholine), which endows caffeine with its stimulant effects; adenosine functions as 
an inhibitory neurotransmitter that suppresses activity in the central nervous system. 
Heart palpitations are caused by blockade of the adenosine A1 receptor [45]. 
Supplementation with nitrate is commonly consumed as beetroot juice or sodium nitrate 
[46]. The doses ranging from 300 to 600mg nitrate have shown to improve exercise 
performance [46-48]. Dietary nitrate supplementation has been reported to be in 
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association with a lower ATP cost of muscle force production [49] and an increase in the 
mitochondrial ratio of phosphate radicals esterified to atoms of O2 consumed [50]. The 
ingestion of nitrate can increase muscle oxygenation in contracting skeletal muscle [51]. 
During the nitrate reduction process, nitrate is reduced to nitrite [52]. Nitrite anion is 
recognized as a transient species that acts in the physiological regulation of blood flow 
and blood pressure [53, 54]. Nitrite exerts these effects in the body via its conversion to 
functional nitrogen oxides, including nitric oxide [54]. These physiological effects 
possibly account for the increased exercise tolerance [49, 51, 55] and exercise 
performance that has been reported following nitrate supplementation [56, 57].  
Statement of the Problem 
Will consuming a PWS containing caffeine, creatine nitrate, β-alanine, arginine 
α-ketoglutarate, and N-acetyl tyrosine affect acute exercise or cognitive function?  
Purpose of the Study 
The purpose of this study was to determine whether acute ingestion or 7 days of 
daily consumption of PWS’s affect exercise and/or cognitive function. The secondary 
purpose of this study was to determine whether PWS and 1.5 times recommended dose 
is safe or not. 
General Study Overview 
This study was conducted in a randomized, double-blind, placebo-controlled trial 
and cross-over manner. The independent variable was the nutritional supplementation. 
Dependent variables included resting energy expenditure; HR and BP; readiness to 
perform visual analogue scale (VAS); cognitive function test; strength endurance and 
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anaerobic sprint capacity; standard clinical chemistry panel; sleep quality questionnaire; 
and caffeine tolerance questionnaire. Subjects signed a study consent form and 
underwent medical examination and familiarized to the study protocol. At day 0 testing 
session, participants were randomized to one of double-labeled supplement treatments; 
PLA, PWS, or PWS150, and then they received alternate supplement in a counter-
balanced fashion following a 7-day washout period. Participants were instructed to 
ingest 12g of supplement immediately prior to exercise on training days and around 
noon on non-training days and maintain their current diet throughout the study. The data 
were collected prior to, following acute ingestion, after 7 days of ingestion, and 
following an acute dose after 7 days of supplementation. In addition, participants 
recorded a 4-day food-log including three weekdays and one weekend day during each 
washout period. The volunteers were asked to check-in the Exercise and Sport Nutrition 
Lab at Texas A&M University at days 2 and 4 to conduct a Stroop Color Test, Readiness 
to Perform VAS, sleep quality questionnaire, and caffeine tolerance questionnaire. On 
day 7, participants performed same tests as performed during the day 0 testing session. 
Hypotheses 
H01:   PWS supplementation will increase resting energy expenditure. 
H02:   PWS supplementation will increase heart rate and blood pressure. 
H03:   PWS supplementation will improve perceptions of readiness to 
          perform. 
H04:   PWS supplementation will improve markers of cognitive function. 
H05:   PWS supplementation will affect exercise performance. 
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H06:   There will be no significant differences in markers of health. 
H07:   There will be no significant differences in sleep quality inventory. 
H08:   There will be no significant differences in caffeine tolerance 
           inventory. 
Delimitations 
 This study was conducted under the following guidelines: 
1. Nineteen (N = 19) recreationally active men and women between the ages 
of 18 – 40 years were recruited for the study. 
2. Subjects had at least 6 months immediate prior history of resistance 
training including bench press and leg press/squat. 
3. Eligible participants took part in familiarization (FAM) session during 
which time they were informed of the study protocol, filled out necessary 
forms including an informed consent form and a general screening form. 
Then, they completed a one repetition max bench press and leg press test 
and a practice anaerobic sprint test on a cycle ergometer.  
4. Participants were advised to maintain a consistent workout and dietary 
regimen throughout the duration of the study. 
5. Participants had to refrain from exercise, caffeine, and use of over-the-
counter stimulants for 48-hrs prior to each testing session. 
6. Participants were fasted for at least 12-hrs prior to each testing session. 
7. Participants performed to their maximal ability on all strength and 
anaerobic sprint tests. 
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8. Participants were instructed to consume all supplements and report any 
disorder(s) in weekly side-effects questionnaires. 
Limitations 
1. The participants were individuals from the Texas A&M University 
community and surrounding fitness facilities that responded to 
recruitment fliers and emails; therefore the selection process was not truly 
random. 
2. There were some variations in testing times and dietary intake, although 
all efforts were made to conduct testing sessions at the same approximate 
time to account for diurnal variations and subjects were instructed to 
maintain a consistent diet throughout the duration of the study. 
3. Motivation and effort during performance throughout testing may not 
have been 100% at each testing session. 
4. All laboratory equipment was calibrated according to manufacturer 
guidelines and all samples were run in duplicate to reduce likelihood or 
error. However, there are innate limitations of the laboratory equipment 
that are used for data collection and analysis. 
Assumptions 
1. Participants followed the protocol that was explained to them during the 
FAM session. 
2. Participants answered the entrance questionnaires accurately and honestly 
prior to being accepted into the study. 
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3. Participants adhered to the supplementation protocol and testing schedule. 
4. All laboratory equipment was calibrated and functioning properly prior to 
all testing sessions. 
5. The population, which the sample was drawn from, was normally 
distributed. 
6. The variance among the population sample was approximately equal. 
7. The sample was randomly assigned to the different supplement groups. 
8. Participants maintained a consistent dietary intake and exercise regimen 
throughout the duration of the study. 
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CHAPTER II  
REVIEW OF THE LITERATURE 
Introduction 
Scientific research on ergogenic supplements has led manufacturers to introduce 
preworkout energy drinks (ED) to the market. ED are a unique category within the 
beverage industry and typically contain glucose, caffeine, and/or nutrients that are often 
used to improve energy metabolism, mental focus, strength, and power [19, 29, 58]. 
Numerous studies have shown that some of the individual ingredients contained in PWS 
improve physical performance as each individual ingredient is associated with a different 
physiological mechanism [16, 59, 60]. For example, acute use of caffeine as the main 
active ingredient has shown to increase muscular strength, power, and endurance [36, 
61, 62]. In addition, caffeine produces mild central nervous system stimulation, reducing 
fatigue and increasing concentration and alertness [44, 63]. Except for sugar-free 
versions, all ED contain sugars in the form of monomers glucose and fructose, the dimer 
sucrose, and the synthetic polymer maltodextrins, also known as glucose polymers [64, 
65]. Investigators have documented the improved exercise performance in athletes using 
carbohydrate beverages, compared to water or other PLA beverages [66-68].  
Some studies have shown that using diverse multi-ingredient PWS mediates 
improving time to fatigue [69, 70], increasing mental alertness [71], and enhancement of 
muscular strength [24]. However, the combined effects of nutritional ingredients needs 
to be more investigated despite increasing the popularity of multi-ingredient PWS. The 
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following scientific support serves as the basis for specific ingredients used in the most 
PWS.  
Caffeine 
Table 2.1 provides the summary of some studies investigating the effects of 
caffeine supplementation. In the current study, we planned to use 300mg/day and 
400mg/day caffeine anhydrous in two doses of PWS. Caffeine has shown to be an 
effective ergogenic aid for enhancing sport performance in trained athletes when 
consumed in low-to-moderate dosages (~3-6mg/kg) [16]. For example, acute anhydrous 
caffeine ingestion (2-5mg/kg-1) improved resistance exercise performance (5-8%) by 
allowing the consumer to enhance exercise intensity, leading to an increased training 
volume [60]. In the brain, adenosine is an inhibitory neurotransmitter. This 
means, adenosine functions as a central nervous system depressant. In normal 
conditions, it promotes sleep and suppresses arousal. Adenosine generally decreases the 
concentration of major neurotransmitters, including serotonin, dopamine, acetylcholine, 
norepinephrine and glutamate. Caffeine functions as an antagonist to A1 and A2A 
adenosine receptors, and increases the concentration of these major neurotransmitters 
[72]; thus, caffeine can improve mental and physical performance [73-75] and reducing 
pain and fatigue [60, 76-78] associated with high-intensity resistance training. Caffeine 
has been broadly studied as an ergogenic aid for increased energy, improved exercise 
performance, and increased fat oxidation [79-82]. The breadth of research spans across 
several decades and is fairly unequivocal. What remains to be somewhat elucidated is 
the exact physiological mechanism that makes this ingredient beneficial to sport 
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performance. Ivy et al. [82] indicated that caffeine ingestion (160mg) 40 min prior to 
exercise improves endurance performance in PWS vs. PLA group (3,690 ± 64 sec vs. 
3,874 ± 93 sec). Graham et al. [83] examined the effect of ingesting caffeine 
(4.45mg/kg) in coffee or in water 1 hr prior to exercise. The endurance time showed a 
significant improvement in the supplement group (7.5-10 min). Based on these findings, 
the investigators concluded: 1) caffeine has the potential to increase endurance 
performance and 2) caffeine in isolation from coffee can prominently improve endurance 
capacity.   
Exercise physiologists have also investigated the caffeine phenomenon, and 
tested for the possibility that it might improve high intensity relatively short-term 
performance. Doherty et al. [7] indicated that caffeine ingestion (5mg/kg-1) increased 
mean power output in high-intensity cycling. Green et al. [84] found caffeine (~6mg/kg) 
to moderately enhance resistance training performance. The findings of similar rating of 
perceived exertion concurrent with higher repetitions suggested that caffeine can blunt 
pain responses, possibly delaying fatigue in high-intensity resistance training. Therefore, 
other mechanisms were cited to explain the effect of caffeine on performance 
improvement, such as the central nervous system, a direct effect on skeletal muscle, and 
increased motor unit recruitment [85]. Kalmar and Cafarelli [85], suggested that caffeine 
functions as an antagonist on adenosine receptors to block the inhibitive actions of 
adenosine on neurotransmitter (e.g., dopamine) release. Davis et al. [44] also concluded 
that caffeine may function to impede fatigue by the action of blocking adenosine 
receptor sites and increasing the release of excitatory neurotransmitters, especially 
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dopamine. Therefore, where the central nervous system is concerned, caffeine may act to 
increase excitability of the motor neuron pool by binding to competing adenosine 
receptor sites. In another study, Beck et al. [36] examined the acute effects of caffeine 
supplementation on strength, muscular endurance, and anaerobic capacity on resistance 
trained males. Caffeine ingestion was effective for increasing bench press 1RM (2.1 kg = 
2.1%). Daniels et al. [86] examined the effects of caffeine ingestion, 45 min prior to 
exercise, on BP, HR, and forearm blood flow during dynamic leg exercise on trained 
caffeine-naive cyclists. Before exercise, caffeine increased both SBP (17%) and mean 
arterial pressure (11%). During dynamic exercise, caffeine attenuated the increase in 
forearm blood flow (53%) and forearm vascular conductance (50%). SBP and mean 
arterial pressure were also higher during exercise plus caffeine; however, these increases 
were secondary to the effects of caffeine on resting BP. No significant differences were 
observed in HR. The authors concluded that the caffeine-induced alterations were 
probably due to antagonism of adenosine receptors. Caffeine has been shown to inhibit 
both A1 and A2 adenosine receptors. The A2 receptors are primarily responsible for 
adenosine’s vasodilatory effects. The observation that caffeine attenuated the increase in 
forearm blood flow during exercise suggested that caffeine may offset adenosine-
provoked dilation in other regional circulations under these circumstances. Astorino et 
al. [87] examined the effect of caffeine (6mg/kg) ingestion 1 hr prior to exercise, on 
cardiovascular function in resistance-trained males during resistance training. The HR 
was significantly higher at rest and bench press, in the treatment compared to PLA group 
(+10 beats/min). No difference was detected for DBP for time or treatment. SBP was 
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significantly increased in both the caffeine and PLA treatments, as a result of an acute 
bout of resistance exercise (+8-10 mmHg). 
There is a wealth of research showing that the ingestion of ED containing 
caffeine can benefit cognitive performance, particularly alertness and vigilance, mood, 
and perception of fatigue [88-92]. In addition, many athletes believe supplementation 
prior to training will result in greater focus, quicker reaction time, and increased power 
[24, 93, 94]. It is possible that the addition of caffeine as a psychopharmacologically 
active substance affects memory processes even under non-demanding task conditions 
[24, 95]. Smith and Rogers [38] studied the effects of 0, 12.5, 25, 50, and 100mg 
caffeine on cognitive performance, mood and thirst in adults with low and moderate to 
high habitual caffeine intakes. Effects on performance and mood confirmed 
psychostimulant action of caffeine. All doses of caffeine significantly affected cognitive 
performance (p < 0.05). They concluded that after overnight caffeine abstinence, 
caffeine can significantly affect cognitive performance, mood, and thirst at doses within 
and even lower than the range of amounts of caffeine contained in a single serving of 
popular caffeine-containing drinks. Giles et al. [96] studied the effects of caffeine, 
taurine, and glucose alone and in combination on cognitive performance and mood in 
24-hrs caffeine-abstained habitual caffeine consumers. Using a randomized, double-
blind, mixed design, habitual caffeine consumers who were 24-hrs caffeine deprived 
received one of four treatments (200mg caffeine/0mg taurine, 0mg caffeine/2,000mg 
taurine, 200mg caffeine/2,000mg taurine, 0mg caffeine/0mg taurine), on each of four 
separate days, separated by a 3-day washout period. Between-participants treatment was 
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a glucose drink (50g glucose, PLA). Salivary cortisol, mood, and HR were measured. An 
attention task was administered 30-min post-treatment, followed by a working memory 
and reaction time task 60-min post-treatment. Caffeine enhanced executive control 
(caffeine + taurine = 84.2 ± 26.1, caffeine = 87.4 ± 26.5, taurine = 96.3 ± 30.3, PLA = 
97.1 ± 22.3) and reduced simple and choice reaction time. Taurine increased choice 
reaction time but reduced reaction time in the working memory tasks. Glucose alone 
slowed choice reaction time (caffeine + taurine = 181.3 ± 13.6, caffeine = 185.7 ± 14.3, 
taurine = 195.1 ±17.1, PLA = 213.8 ± 19.9). Glucose in combination with caffeine, 
enhanced object working memory and in combination with taurine, enhanced orienting 
attention (caffeine + taurine = 44.0 ± 19.9, caffeine = 29.7 ± 14.2, taurine = 39.4 ± 17.7, 
PLA = 36.0 ± 13.6). No effects were found for salivary cortisol or HR. Caffeine, not 
taurine or glucose, was likely responsible for reported changes in cognitive performance 
following consumption of ED. 
Some studies reported that caffeine had no effect on exercise performance. For 
example, Paton et al. [97] investigated the effect of caffeine ingestion on performance in 
a test that simulated the repeated sprints of team sports. In a randomized double-blind 
cross-over experiment, team-sport athletes ingested either caffeine (6mg/kg-1) or a PLA 
60 min before performing a repeated 20-m sprint test. The observed effect of caffeine 
ingestion on mean sprint performance and fatigue over 10 sprints was negligible.  
Glaister et al. [98] evaluated the effects of caffeine supplementation on sprint cycling 
performance and to determine if there was a dose-response effect using a randomized, 
double-blind, placebo-controlled design. Subjects ingested caffeine or PLA 1 hr prior to 
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each exercise performance. To examine dose-response effects, caffeine doses of 2, 4, 6, 
8, and 10mg/kg were used. The results of this study show that caffeine supplementation 
has no effect on short-duration sprint cycling performance, irrespective of the dosage 
used. 
While numerous studies have supported the efficacy of caffeine supplementation 
for delaying fatigue [44], strength [36], power [7], aerobic performance [83, 99], and 
cognitive function [95, 96, 100], there have been conflicting results. Based on the 
literature, the doses used in our study would seemingly affect exercise performance [61, 
101] and/or cognitive function [102, 103].  
Creatine  
 Table 2.2 provides the summary of some studies investigating the effects of 
creatine (Cr) supplementation. In the present study, we planned to use 1.34g/day and 
2.01g/day Cr nitrate in two doses of PWS. Cr is a nitrogenous amino acid derivative 
naturally found in skeletal muscle, brain, testes, and other organs [104]. Human body 
can endogenously synthesize Cr from three amino acids–glycine, arginine, and 
methionine, primarily in the liver, pancreas, and kidneys [105]. Animal products such as 
fresh fish and meat and various synthetic Cr supplements are sources of dietary Cr. 
Approximately, 90-95% of Cr in the body is stored in the skeletal muscle, where it 
serves as an energy source and a small amounts found in the brain and testes (~5%) 
[106]. In an average 70 kg adult, the total Cr pool in the body amounts to about 120g; 
this pool is subject to continuous degradation to creatinine, which is excreted in 
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Table 2.1 Effect of Caffeine Supplementation 
Study 
(year) 
Design Population Protocol 
Diet 
control 
Dosage/Duration 
Additional 
supplements 
Measurements Major Findings 
Ivy et al. 
[82] 
(2009) 
Randomized, 
double-blind, 
cross-over 
6 male (23 yr) 
and 6 female (27 
yr) trained 
cyclists 
60 min of cycling at 70% Wmax No 160mg taken 45 min before exercise Niacin, 
carbohydrate, 
taurine, 
glucuronolact
one vitamins 
B6 and B12 
Ventilation,  
O2, CO2 
production, and 
RER 
Improved endurance 
performance 
Graham et 
al. [83] 
(1998) 
Double-blind, 
placebo-controlled 
9 endurance 
runner young 
males (21-47 yr) 
VO2 max test and 20–30 min 
run at 85% (5 trials) in a 
separate day  
No 4.45mg/kg taken 60 min before 
exercise 
No VO2 max and 
blood variables 
No effect on caffeine 
bioavailability. No increase in 
endurance 
Beck et al. 
[36] 
(2006) 
Randomized, 
double-blind, 
placebo-
controlled, parallel 
design 
37 resistance-
trained males 
(20 ± 2 yr) 
Wingate test, strength tests No 201mg taken 60 min before exercise  Vitamins B6, 
C, niacin, 
pantothenic 
acid 
Anaerobic 
capacity, upper 
and lower body 
strength, peak 
power 
Increase in bench press lRM, 
No effect on leg extension l-
RM, leg extension total 
volume, bench press total 
volume, peak power, and 
mean power 
Daniels et 
al. [86] 
(1998) 
Double-blind, 
placebo-controlled 
10 trained 
cyclists, 3 males, 
7 females (30 ± 
0.3 yr) 
55 min of cycle ergometry at 
65% of VO2 max (4 trials) 
No 6mg/kg taken either 45 min or 100 
min before exercise 
No Hemodynamic 
and blood 
variables 
Alter in cardiovascular 
response to dynamic exercise 
in a manner that may modify 
regional blood flow and 
conductance 
Astorino et 
al. [60] 
(2010) 
Randomized, 
single-blind, 
counterbalanced, 
cross-over  
15 active males 
(26 ± 3 yr) 
Maximal knee extension and 
flexion of the dominant leg (3 
trials separated by 48 h) 
No 2 or 5mg.kg taken 60 min before 
exercise  
No Knee 
extension/flexion 
torque, power, 
and total work 
Ergogenic for maximal knee 
extension/ flexion exercise 
Smith and 
Rogers 
[38] 
(2000) 
Double-blind, 
within-subjects, 
placebo-controlled 
11 males and 12 
females (18-56 
yr) 
Two performance tests, a long 
duration simple reaction time 
task and a rapid visual 
information processing task, 
and a mood questionnaire 
No 5 treatments (0, 12.5, 25, 50, and 
100mg caffeine) administered once 
per week 
No Cognitive 
performance, 
mood, and thirst 
Improved cognitive 
performance, mood, and thirst 
at doses within and lower than 
range of amounts of caffeine 
Giles et al. 
[96] 
(2012) 
Randomized, 
double-blind, 
mixed design 
18 males and 30 
females (20 ± 1 
yr) 
Multiple measures of caffeine 
withdrawal symptoms, mood, 
and cognitive performance 
using questionnaires 
No One of four treatments (200mg 
caffeine/0mg taurine, 0mg 
caffeine/2,000mg taurine, 200mg 
caffeine/2,000 mg taurine, 0mg 
caffeine/0mg taurine), on each of four 
separate days, 60 min before test 
Taurine Executive 
control, working 
memory, and 
reaction time 
Improved cognitive 
performance 
Paton et al. 
[97] 
(2001) 
Randomized, 
double-blind, 
cross-over 
16 male sport-
science students 
(22 ± 3 yr) 
10 sprints, each performed 
within 10 sec, followed by rest 
for remainder of each 10 sec 
No 6mg·kg-1, 60 min before performing 
the test 
No Exercise 
performance 
Caffeine ingestion on mean 
sprint performance and fatigue 
was negligible 
Glaister et 
al. [98] 
(2012) 
Randomized, 
double-blind, 
placebo-controlled 
17 well-trained 
men (24 ± 6 yr) 
7 maximal 10-sec sprint trials 
on a cycle ergometer 
No 2, 4, 6, 8, and 10mg/kg, 60 min 
before exercise 
No Exercise 
performance and 
blood variables 
No effect on short-duration 
sprint cycling performance, 
irrespective of the dosage used 
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the urine at a rate of about 2g/day. Replenishment of Cr at a similar rate is achieved by a 
combination of dietary intake and endogenous synthesis. Once in muscle cells, nearly 
65% of Cr is phosphorylated to produce phosphocreatine (PCr), while the remaining 
content of Cr is stored as free Cr [107]. PCr as a high energy compound can donate a 
phosphate group to adenosine diphosphate (ADP) to create adenosine triphosphate 
(ATP) via the enzymatic reaction of creatine kinase (CK). ATP is the initial source of 
energy for muscle contraction [108].   
Cr obtained either from endogenous synthesis or by ingestion of Cr-containing 
food is transported into muscle, brain, heart, and many other tissues with high and 
fluctuating energy demands by a specific Cr transporter [109]. Imported Cr is charged to 
the high energy compound PCr by the action of either strictly soluble, cytosolic CK, by 
CK coupled to glycolysis or by mitochondrial CK coupled to oxidative phosphorylation. 
In a resting cell, this results, at equilibrium, in a distribution of the total Cr pool into 
approximately two-thirds (PCr) and one-third (Cr) and in a very high ATP/ADP ratio (≥ 
100:1). A fraction of cytosolic isoforms of CK are specifically associated with ATP-
consuming processes such as the myofibrillar actomyosin ATPase, the sarcoplasmic 
reticulum Ca2+-ATPase, the plasma membrane Na+/K+-ATPase, and the ATP-gated K+- 
channel or ATP-requiring constituents for cell signaling [108]. 
Within these functional micro-compartments, CK regenerates the utilized ATP, 
drawing from the large PCr pool. These micro compartments with associated CK 
represent the ATP/PCr-consuming side of the CK/PCr system. At the ATP/PCr-
generating side of the system, there are the glycogenolytic/glycolytic CK-g micro 
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compartments and the mitochondrial CK micro compartment connected to oxidative 
phosphorylation and energy channeling reactions inside the mitochondrion [110]. 
Mitochondrial CK is located in the intermembrane space of mitochondria with 
preferential access to ATP generated by oxidative phosphorylation via adenine 
nucleotide translocator of the mitochondrial inner membrane. This mitochondrial ATP is 
trans-phosphorylated into PCr that then leaves the mitochondria. This route of ATP 
generation is most important for refilling the PCr energy store in oxidative tissues, e.g. 
upon extensive stimulation of muscle contraction and thus is relevant for recovery after 
exhausting exercise [108].  
Goldberg and Bechtel [111] evaluated speed, strength, and power before, during, 
and after a low dose (3g/day) of Cr or PLA supplementation among trained athletes 
involved in off-season weight training program. The varsity football and track athletes 
ingested three gel capsules, each containing 1g Cr or PLA once a day, for 14 consecutive 
days. Participants were tested on day 0, 7, and 14 for 1RM bench press, vertical jump, 
40-yard sprint, leg sled, and leg extension. Results from this study suggested that 3g/day 
of oral Cr supplementation in trained athletes over a 14-day period can improve vertical 
jump but no other activities. Harris et al. [112] examined two doses of Cr to determine 
whether Cr supplementation can increase in the total Cr pool in muscle. An additional 
effect of exercise upon uptake into muscle was also investigated. Low doses of Cr (1g or 
less in water) produced only a modest rise in the plasma Cr concentration, whereas 5g Cr 
resulted in a mean peak after 1 hr. Repeated dosing with 5g every 2 hrs sustained the 
plasma concentration at around 1,000μmol/l. Supplementation with 5g of Cr four or six 
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times a day for 2 or more days resulted in a significant increase in total Cr content of the 
quadriceps femoris muscle. Thompson et al. [113] examined the effect of a relatively 
low dose of Cr (2g/day) during a six weeks course on skeletal muscle metabolism and 
oxygen supply in a group of training athletes. There was no effect of Cr on metabolite 
ratios at rest or on metabolism during exercise and recovery from exercise. Muscle 
oxygen supply and exercise performance were not improved by Cr when compared to 
PLA treated subjects. They concluded that oral Cr supplementation at 2g daily has no 
effect on muscle Cr concentration, muscle oxygen supply or muscle aerobic or anaerobic 
metabolism during endurance exercise. 
It seems that chronic supplementation with Cr at low-dose might cause ergogenic 
effects. For example, Rawson et al. [114] examined the effects of low-dose Cr 
supplementation (2.3g/day) on body composition, muscle function, and body Cr 
retention for 6 weeks in a double-blind placebo-controlled fashion. Participants were 
tested before supplementation and retested after supplementation. Testing included body 
composition, maximal strength, muscle fatigue, and plasma Cr concentration. The results 
from this study indicated that chronic ingestion of a low-dose of Cr significantly 
increased plasma Cr concentration and enhanced resistance to fatigue during repeated 
bouts of high-intensity contractions. Based on the literature, the doses used in our study 
would seemingly have little to no ergogenic effect. 
Nitrate 
In the present study, we planned to use 660mg and 990mg nitrate in two doses of 
PWS. Nitrate (NO3
–) is a naturally occurring anion in the human body with an inert 
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oxidative end product of endogenous nitric oxide (NO) metabolism [115]. Nitrate may 
be reduced to nitrite and NO in vivo, particularly in environments of hypoxia and 
acidosis [46]. The physiological actions of nitrate are reduction of BP [116], 
improvement of vascular compliance [117], and attenuation of oxidative stress [118] 
following consumption. Beetroot juice (BRJ) contains high amounts of nitrate 
(>250mg/100g of fresh weight), among other foods rich in nitrate include spinach, 
lettuce, celery, and carrot juice [119]. Circulating nitrate can be reduced to nitrite by 
commensal bacteria in the oral cavity and by specific enzymes (e.g., xanthine oxidase) 
within tissues. Nitrite can be metabolized by mitochondria to form NO in competition 
with oxygen [120]. NO is a signaling molecule that can diffuse through biological 
membranes. NO can be formed in the endothelium by NO synthase, which stimulates 
vasodilatation by interacting with vascular smooth muscle resulting in increased blood 
flow [121, 122]. BRJ would seem likely to improve markers of exercise performance. 
The impact of BRJ ingestion on power output, VO2, and cycling time trial performance 
was investigated by Lansley et al. [57] using competitive cyclists who consumed either 
0.5L BRJ (384mg of NO3
−) or PLA containing nitrate-depleted BRJ (0.29mg of NO3
−) 
before each time trial of 4 km or 16 km. BRJ consumption increased plasma nitrite by 
138% and resulted in significantly reduced time to completion and increased power 
output during both the 4 km (2.8% and 5%, respectively) and 16 km time trials (2.7% 
and 6%, respectively) compared to PLA. Bailey et al. [51] supplemented healthy men 
with 0.5L of BRJ (341mg of NO3
−) or a low-calorie blackcurrant juice cordial 
(negligible NO3
− content) for 6 days, and they performed moderate (80% gas exchange 
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threshold) and intense cycling (70% of the  difference between the power output at the 
gas exchange threshold and VO2 peak) protocols during the last 3 days. BRJ ingestion 
increased the average plasma nitrite by 96% and reduced muscle deoxyhemoglobin 
amplitude by 13%, suggesting that fractional oxygen extraction was reduced. In 
addition, BRJ consumption reduced the amplitude of the VO2 slow component, defined 
as a delayed onset of VO2 consumption during high intensity exercise. The authors 
concluded that increased dietary inorganic nitrate consumption from BRJ has the 
potential to improve high-intensity exercise tolerance. 
Only few studies have been published that investigated the effect of BRJ on 
resistance exercise performance [123-125]. The results of these BRJ studies are 
equivocal, with the overarching theme being a moderate increase in resistance exercise 
performance. Bailey et al. [49] recruited recreationally active men to consume either 
0.5L/day of BRJ (316mg NO3
−) or a PLA (blackcurrant juice cordial with negligible 
NO3
− content) for 6 days. During the last 3 days of supplementation, participants 
completed low and high (15% and 30% maximal voluntary isometric contractions, 
respectively) intensity “step” knee extension tests. The increase in pulmonary VO2 from 
rest to low-intensity exercise was reduced by 25% following dietary nitrate 
supplementation. Furthermore, BRJ ingestion lead to a 36% reduction in the amount of 
PCr degraded during low-intensity exercise (knee extensions) and a 59% reduction 
during high-intensity exercise compared to PLA. These reductions in PCr usage were 
accompanied by a reduction in the total ATP utilization during both high and low- 
density exercise. Several studies indicated either an improvement in exercise 
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performance or exercise efficiency resulting from an acute dose of nitrate, 75-150 min 
before exercise, suggesting effects may occur in a relatively short time frame [57, 126, 
127]. Nitrate has been prescribed in absolute (300–600mg) and relative (6.2mg/kg) 
contents. In relative terms, a 70 kg person prescribed 6.2mg/kg would ingest 
approximately 435mg nitrate [46, 120, 128]. Studies have demonstrated that chronic (3-
15 day) and acute BRJ intake (e.g., ~300mg, 2-2.5 hrs prior to exercise) are associated 
with a consistent enhancement of exercise economy [129]. Therefore, it is likely that the 
doses used in our study would seemingly have an ergogenic effect.   
β-Alanine 
Table 2.3 provides the summary of some studies investigating the effects of β-
alanine supplementation. In the current study, we planned to use 3.2g/day and 4.8g/day 
β-alanine in two doses of PWS. β-alanine is a non-proteogenic amino acid that is 
produced endogenously in the liver. The binding of β-alanine to histidine is the rate-
limiting step in the formation of carnosine within muscle fibers [130]. Carnosine (β-
alanyl-L-histidine) is a cytoplasmic dipeptide, which plays a role in the intracellular 
buffer of hydrogen ions. Carnosine is found in high concentrations in the skeletal muscle 
of both vertebrates and non-vertebrates as well as in the central nervous system [131]. In 
human blood, carnosine is rapidly hydrolyzed to its constituent amino acids due to the 
presence of carnosinase, a specific hydrolyzing enzyme. Following this, β-alanine and 
histidine can then be transported to other organs and tissues. Whilst the carnosinase 
enzyme has been identified in several tissues including the blood, liver and kidney;
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Table 2.2 Effect of Creatine Supplementation 
Study 
(year) 
Design Population Protocol 
Diet 
control 
Dosage/Duration 
Additional 
supplements 
Measurements Major Findings 
Goldberg and 
Bechtel [111] 
(1997) 
Randomized, 
double-blind, 
placebo-
controlled 
34 varsity 
football and 
track athletes 
(18-22 yr) 
1RM bench press, vertical 
jump, 40-yard sprint, leg sled 
using twice body weight and 
leg extension 
No 3g/day before and 
during for 14 
consecutive days 
No Exercise performance Anaerobic performance was enhanced in 
the vertical jump but not in other activities 
Harris et al. 
[112] (1992) 
Randomized, 
dose dependent 
5 females and 12 
males (20-62 yr) 
60 min hard exercise per day 
using one leg 
No Two doses, low dose 
(1g or less), high 
dose (5g) 
No Needle biopsy, blood 
variables, exercise 
performance 
Supplementation with 5g resulted in a 
significant increase in total Cr content of 
the quadriceps femoris muscle 
Thompson et 
al. [113] 
(1996) 
Randomized, 
placebo-
controlled 
10 female 
athletes 
Plantar flexion of the right 
ankle, lifting a weight of 10% 
lean body mass a distance of 7 
cm at a rate of 30 min-1 
No 2g/day for 6 weeks  No Muscle biopsy No effect on muscle creatine 
concentration, muscle oxygen supply or 
muscle aerobic or anaerobic metabolism 
Rawson et al. 
[114] (2011) 
Randomized, 
double-blind, 
placebo- 
controlled 
8 females, 12 
males (21 ± 2 yr) 
Three-repetition maximum 
concentric knee extension test 
at 180 degrees/sec and five 
sets of 30 concentric knee 
extensions at 180 degrees/sec 
with a 1 min rest between sets 
No ~ 2.3g/day for 6 
weeks 
No Blood variables, 
Exercise performance 
Significant increase in plasma Cr 
concentration and enhanced resistance to 
fatigue during repeated bouts of high-
intensity contractions 
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critically it is not found in skeletal muscle. Therefore, oral carnosine supplementation is 
an inefficient method of augmenting muscle carnosine levels in humans, as ingested 
carnosine is ultimately metabolized before reaching skeletal muscle [132, 133]. β-
alanine as the rate-limiting precursor to carnosine synthesis has been shown to augment 
carnosine and may therefore improve exercise performance [134].   
It typically takes a number of weeks (at least 2 weeks) for β-alanine 
supplementation to yield meaningful increases in muscle carnosine content. As such, it is 
unlikely that β-alanine is the primary ingredient improving performance outcomes in 
studies utilizing acute, one-time supplementation [132]. For example, Glen et al. [135] 
evaluated the effects of acute β-alanine supplementation (1.6g) on anaerobic 
performance among athletes in a randomized, double-blind study. Participants completed 
two supplement trials: 1) PLA (34g dextrose) and 2) β-alanine (1.6g β-alanine + 34g 
dextrose). Thirty minutes after supplementation, participants performed three repeated 
Wingate anaerobic capacity tests with 2 min of active rest after each. Fatigue index, 
mean power, and peak power were measured during each Wingate test. Lactate, HR, and 
rating of perceived exertion were measured at rest, immediately after each Wingate test, 
and after each active rest period. Findings suggested that an acute dose of β-alanine 
decreased rating of perceived exertion during anaerobic power activities in athletes; 
however, no significant supplementation effect was observed for any performance or 
physiological variable. Invernizzi et al. [136] investigated the acute effects of carnosine 
and β-alanine ingestion on anaerobic intermittent running performance on healthy, 
young, active males in a randomized, cross-over design. Participants performed running-
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based anaerobic test twice (with 30 min recovery in between) on two separate occasions. 
The test consisted of 6 × 35-m sprints interspersed with 10 sec rests after acute ingestion 
(4 hrs before the test) of either 2g L-carnosine + 2g β-alanine or PLA. The overall 
performance decreased (test 1 vs test 2, carnosine + β-alanine: 32.8 ± 1.3 sec, 33.4 ± 1.2 
sec; PLA: 32.9 ± 1.0 sec, 33.6 ± 1.2 sec), pain after the test increased almost in the same 
way in both groups, and rating of perceived exertion did not show any difference. In 
conclusion, these findings suggest that acute administration of carnosine + β-alanine 
might have a very small enhancing effect on anaerobic sprint performance. 
In studies extending over 4 to 8 weeks, the likelihood of β-alanine contributing to 
improvements in performance is greater [132]. For example, Smith et al. [137] evaluated 
the effects of combining β-alanine supplementation with high-intensity interval training 
on endurance performance and aerobic metabolism in recreationally active college-aged 
men. All subjects supplemented four times per day (total of 6g/day) for the first 21-days, 
followed by two times per day (3g/day) for the subsequent 21 days. The results indicated 
that β-alanine supplementation in combination with high-intensity interval training 
resulted in significant improvements in VO2 peak and time to fatigue during exercise. 
Kern et al. [130] studied the effects of β-alanine supplementation (4g/day) on 
performance for 8 weeks in collegiate wrestlers and football players. Performance 
improvements were greatest in the football players’ supplement group, decreasing 300 
shuttle time by 1.1 sec (vs. 0.4 sec PLA) and increasing flexed-arm hang (3.0 vs. 0.39 
sec). They concluded that β-alanine has the ability to improve performance in previously 
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trained athletes. Based on the literature, it is not likely that β-alanine supplementation for 
a 7-day period to have an ergogenic effect.   
L-Arginine 
Table 2.4 provides the summary of some studies investigating the effects of L-
arginine supplementation. In the present study, we planned to use 2g/day and 3g/day L-
arginine in two doses of PWS. The semi-essential amino acid L-arginine is critical factor 
in a variety of physiological conditions. L-arginine is available in several nutritional 
supplements and food such as nuts, fish, pork, chicken, dairy products, and egg. It is one 
of the building blocks of proteins in the body. Among many important proteins in which 
L-arginine is included are hormones, histones, collagen, and intracellular structural 
proteins. It serves as a substrate for Cr, urea, and NO synthesis. L-arginine regulates 
interorgan metabolism of energy substrates and the function of multiple organs. L-
arginine is not considered as an “essential” amino acid since human body can synthesize 
it “de novo” from glutamine, glutamate, and proline. This means the body produces 
adequate functional contents on its own to meet most normal physiological demands; 
however, during times of stress or increased demand, for example, in exercise or disease, 
further amounts of L-arginine is needed from external dietary sources [138-142]. Wax et 
al. [143] examined the efficacy of acute ingestion of L-arginine on muscular strength 
and endurance in resistance trained and untrained men in a randomized, double-blind 
cross-over design. Participants ingested either 3g of L-arginine or PLA (microcrystalline 
cellulose), 45 min prior to a resistance exercise protocol. The results from this study 
indicated that acute L-arginine supplementation provides no ergogenic benefit on 1RM  
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Table 2.3 Effect of β-Alanine Supplementation 
Study 
(year) 
Design Population Protocol 
Diet 
control 
Dosage/Duration 
Additional 
supplements 
Measurements Major Findings 
Glen et al. 
[135] (2015) 
Randomized, 
double blind, 
placebo-controlled, 
cross-over 
12 trained, 
competitively active 
female cyclists (26 
± 1 yr) 
3 repeated Wingate 
cycling tests with 2 
min of active rest 
after each 
No 1.6g, 30 minutes 
before exercise 
No Exercise 
performance, HR, 
blood variables, 
rating of perceived 
exertion 
Acute dose of β-alanine decreased rating 
of perceived exertion during anaerobic 
power activities. No effects on any 
performance or physiological variable 
Invernizzi et 
al. [136] 
(2013) 
Randomized, 
double blind, 
counterbalanced, 
cross-over, placebo-
controlled 
12 healthy males 
(21 ± 4 yr) 
6 × 35-m sprints 
interspersed with 10 
sec rests 
No 2g, 4 hrs before the 
test 
L-carnosine 
Carnosine 
Exercise 
performance, blood 
variables, 
Acute ingestion of carnosine + β-alanine 
did not influence the cytokine response 
to exercise but had a very small 
enhancing effect on anaerobic sprint 
performance 
Smith et al. 
[137] (2009) 
Randomized, 
placebo-controlled, 
double-blind 
46 recreationally 
active males (22 ± 
2 yr) 
Four, 2-min work 
bouts on a cycle 
ergometer 
No First 3 weeks: 
6g/day, second 3 
weeks: 3g/day 
No VO2 Peak, time to 
fatigue, ventilatory 
threshold, total 
work done 
Improved high intensity interval 
training, endurance performance  
Kern et al. 
[130] (2011)  
Placebo-controlled, 
double-blind 
37 male collegiate 
athletes (19 ± 1 yr) 
Timed 300-yd 
shuttle, 900 flexed-
arm hang 
Yes 4g/day-1 for 8 weeks Vitamin E Blood variables 
body composition 
Improvement in sprinting time, but no 
sufficient power to show significant 
benefits 
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or total load volume as measured by bench press and leg press, regardless of the 
participants’ training status. Olek et al. [144] assessed the effect of an acute dose of L-
arginine in a low dose (2g) 60 min before exercise. They showed that this amount of L-
arginine did not induce any increase in the total work performed or mean power output 
during Wingate cycle tests (30 sec), or VO2 either. Additionally, plasma levels of 
nitrate/nitrite were unchanged after L-arginine supplementation compared to PLA. 
Schaefer et al. [145] investigated the acute effect of L-arginine supplementation (3g) on 
physiological and metabolic changes during exercise. The results indicated that the 
specific L-citrulline increase and the inverse relationship observed between L-citrulline 
and plasma lactate after L-arginine might support that L-arginine supplementation 
enhances the L-arginine-NO pathway during exercise. Nagaya et al. [5] assessed the 
effects of L-arginine supplementation (0.5g/10 kg body weight) for 7 days on 
hemodynamics and exercise capacity in patients with pulmonary hypertension. These 
results indicated that oral supplementation of L-arginine produced a 9% decrease in 
mean pulmonary arterial pressure and a 16% decrease in pulmonary vascular resistance. 
They concluded that L-arginine supplementation may have beneficial effects on 
hemodynamics and exercise capacity. Zajac et al. [146] investigated the effects of L-
arginine (3g) plus L-ornithine (2.2g) and resistance exercise for 3 weeks on serum 
biomarkers including growth hormone and insulin-like growth factor-1. Resting 
hormonal levels did not differ, but increases in growth hormone and insulin-like growth 
factor-1 were observed following exercise and after 1 hr of recovery, suggesting that the 
combination of L-arginine–L-ornithine supplements has potential ergogenic effect. 
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Table 2.4 Effects of L-Arginine Supplementation 
Study (year) Design Population Protocol 
Diet 
control 
Dosage/Duration 
Additional 
supplements 
Measurements Major Findings 
Wax et al. 
[143] (2012) 
Randomized, 
double-blind, 
placebo-controlled, 
cross-over 
8 resistance 
trained and 8 
untrained healthy 
males 
60 % 1RM repetition 
to failure on bench 
press and leg press 
No 3g single dose taken 
before exercise 
No Exercise tests Acute ingestion of L-arginine 
provided no ergogenic benefit 
on 1RM or total load volume 
Olek et al. 
[144] (2010) 
Randomized, 
double-blind, 
placebo-controlled 
16 healthy active 
subjects  
Three 30 sec all-out 
supramaximal Wingate 
tests with 4 min rest 
between tests 
No 2g single dose taken 
60 min before 
exercise 
No Blood variables 
and exercise test 
Neither induced effect on NO 
concentration, nor improved 
physical performance 
Schaefer et al. 
[145] (2002) 
Randomized, 
double-blind, 
placebo-controlled, 
cross-over 
8 healthy men 
(29 ± 4 yr) 
Two tests including 2-
min period at 50 W, 
then workload 
increased by 25 W 
each 2 min to reach the 
maximal power output 
No 3g single dose taken 
60 min before 
exercise 
No Hemodynamic, 
respiratory, 
blood variables, 
and exercise test 
Intravenous L-arginine reduced 
significantly exercise-induced 
increase in plasma lactate and 
ammonia 
Nagaya et al. 
[5] (2001) 
Randomized, 
double-blinded 
4 men and 15 
women with 
pulmonary 
hypertension; (49 
± 4 yr) 
Cardiopulmonary 
exercise tests before 
and 1 week after 
supplementation 
No 1.5g/10 kg body 
weight taken for 1 
week 
No Blood variables 
and 
cardiopulmonary 
exercise tests 
Beneficial effects on 
hemodynamics and exercise 
capacity in patients with 
precapillary pulmonary 
hypertension 
Zajac et al. 
[146] (2010) 
Randomized, 
double-blind, 
placebo-controlled 
17 strength-
trained  male 
athletes (22 ± 1 
yr) 
6 weeks of high 
volume and 3 weeks of 
high-intensity strength 
training 
No 3g twice daily taken 
for 3 weeks 
L-ornithine Blood variables 
and exercise tests 
Elevations in growth hormone 
and insulin like growth factor-1 
in response to an acute 
resistance exercise test after a 
short-term resistance training 
program 
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Based on the literature, the doses used in our study would seemingly have little to no 
ergogenic effect. 
N-Acetyl Tyrosine  
In this study, we planned to use 300mg/day and 460mg/day N-acetyl tyrosine in 
two doses of PWS. N-acetyl tyrosine is a non-essential amino acid that is used by 
cells to synthesize proteins. The physiological basis of tyrosine’s beneficial effects on 
cognitive function is attributed to its role as a precursor for catecholamine 
neurotransmitters, dopamine, and norepinephrine. [147]. These neurotransmitters have a 
key role in a variety of stress-related behaviors. Norepinephrine as a neurotransmitter 
has shown to be critical for modulating the central stress response [148]. During acute 
stress, norepinephrine is depleted, and when further substrate in the form of tyrosine is 
available, the release of norepinephrine increases [149, 150]. Tyrosine influences the 
same neurotransmitter system as the amphetamines that are effective performance-
enhancing compounds, yet they cause several side effects [149]. Acute tyrosine ingestion 
is thought to improve aerobic endurance, muscle strength and endurance, and anaerobic 
power of individuals undergoing severe physiologic stress [151]. In addition, tyrosine 
has the potential as an acute treatment to prevent stress-related decline in cognitive 
function [152]. For example, Deijen and Orlebere [153] evaluated the effect of tyrosine 
on mood, cognitive function, performance, and hemodynamics under stress. Participants 
were tested on two separate days, one test session after ingestion of 100mg/kg tyrosine 
and the other test session after PLA in a random order. While performing a number of 
stress sensitive tasks, volunteers were exposed to a noise stressor. Tyrosine was found to 
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improve the performance on two cognitive tasks which were performed 60 min after 
administration of the medication and which could be characterized as highly sensitive to 
stress. In addition, tyrosine decreased DBP 15 min after ingestion, while 60 min after 
ingestion DBP was the same with tyrosine and PLA. No effects on mood, SBP, and HR 
were found. Grevet et al. [154] evaluated the effects of acute phenylalanine and tyrosine 
depletion on memory, attention, and mood in normal subjects in a randomized, double-
blind, and cross-over study. Participants ingested a nutritionally balanced mixture or a 
similar mixture deficient in phenylalanine and tyrosine. Before and 5 hrs after ingestion 
of the drink, volunteers underwent tests on mood, memory, and attention. Results of the 
memory tests showed that the mixture deficient in phenylalanine and tyrosine impaired 
word recall. The assessment of changes in mood showed that the balanced mixture 
improved scores of as alertness and the mixture deficient in phenylalanine and tyrosine 
induced an opposite effect, increased scores of anxiety. These results suggested that 
tyrosine plasma levels and catecholamines may be important factors in regulating mood 
and memory. Based on the literature, the doses used in our study would seemingly have 
little to no ergogenic effect. 
Pterostilbene 
In the current study, we planned to use 12.5mg/day pterostilbene in PWS150. 
Pterostilbene (trans-3, 5-dimethxy-4-hydroxystilbene) is a stilbenoid chemically similar 
to resveratrol found in blueberries and grapes. It is closely related structurally to 
resveratrol which is a naturally occurring dimethyl ether analogue of resveratrol and 
shows many of the same characteristics as well as its own unique therapeutic potential 
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[155]. Pterostilbene has shown to have several pharmacological benefits for the 
prevention and treatment of many diseases such as cancer [156], diabetes [157], 
cardiovascular degeneration [158], and pain [159]. Antioxidant and anti-inflammatory 
effect of effects of pterostilbene are also shown [160]. The antioxidant activity of 
pterostilbene was demonstrated by methyl linoleate oxidation [160]. It prevents 
generation of hydroxyl radicals [161]. In addition, pterostilbene downregulates 
inflammatory tumor necrosis alpha, interleukin-6, cycloogygenase-2, inducible NO 
synthase, interleukin-1β, monocyte chemotactic protein-1, C-reactive protein, and 
plasminogen activator inhibitor-1 expression by inhibiting the activation of nuclear 
factor kappa B [162]. Pterostilbene has also shown to decrease BP, cholesterol, and 
blood glucose, reverse cognitive decline and it has shown anticancer effects in rats [163-
165]. Human studies using up to 250mg/day have shown the decrease in BP and body 
weight [166, 167]. Apparently, to enhance glycogen replenishment, pterostilbene is 
included in the ingredient profile. Pterostilbene appears to increase insulin sensitivity by 
enhancing hepatic enzymes associated with glucose uptake [168]. Based on our 
knowledge, to date no study has evaluated the impact of pterostilbene supplementation 
on exercise performance, exercise-induced oxidative stress and inflammatory response 
in both trained and sedentary subjects. There is no established recommended dose for 
pterostilbene. Therefore, it not clear whether the doses used in our study would be 
effective or not. 
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Theacrine  
In this study, we planned to use 10mg/day and 20mg/day theacrine in two doses 
of PWS. Theacrine (TeaCor™ Tetramethyluric acid) is a purine alkaloid metabolite of 
caffeine produced as plants mature from young (stage 1) to a more mature plant (stage 3) 
[169]. Abundantly present in Camellia assamica var. kucha, theacrine has been shown to 
increase excitability and locomotor activity in rats similar to caffeine [170, 171]. 
However, theacrine appears to affect the central nervous system different to caffeine. Xu 
et al. [171] indicated that theacrine, co-administered with pentobarbital, significantly 
prolonged sleep time in rats while caffeine and theobromine exhibited the opposite 
effect. Likewise, Wang et al. [172] demonstrated that theacrine has anti-inflammatory 
and analgesic effects, where caffeine does not. Habowski et al. [173] examined the 
effects of theacrine on subjective measures of cognitive function, psychometric indices. 
The 200mg dose of theacrine caused significant improvements in energy (+8.6% vs. -
5.7%) and reductions in fatigue (-6.7% vs. +5.8%). The cohort study demonstrated 
moderate to large effect sizes (0.50-0.71) with the supplement over a 7-day period of 
assessment for the following subjective measures: energy, fatigue, concentration, 
anxiety, motivation to exercise and libido. Tylor et al. [174] investigated the safety and 
non-habituating effects of TeaCrine®, (200mg/day) a nature-identical, chemically 
equivalent bioactive version of theacrine. Results indicated that all values fell within 
normal limits and no group × time interactions were noted for clinical safety markers. 
No evidence of habituation was noted as day 0 values for energy, focus, concentration, 
anxiety, motivation to exercise, and Profile of Mood States remained stable in subjects 
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across the 8-week study protocol. Theacrine would act in a similar manner to caffeine on 
exercise performance when administered in the dose of  200mg [175]. Based on the 
literature, the doses used in our study would seemingly have little to no ergogenic effect. 
Niacinamide 
In this study, we planned to use 60mg/day and 90mg/day niacinamide in two 
doses of PWS. Niacinamide, also known as nicotinic acid amide, is the amide of 
nicotinic acid (vitamin B3/niacin). Niacinamide is a water-soluble B complex vitamin 
[176]. In cells, niacin is incorporated into nicotinamide adenine dinucleotide 
and nicotinamide adenine dinucleotide phosphate [177]. Murray et al. [178] assessed 
how selected physiological and performance responses are affected when the normal 
increase in plasma free fatty acid concentration during exercise is blunted by nicotinic 
acid. The result of the study indicated that blunting the normal rise in free fatty acid 
alters the hormonal response to exercise and reduces the capacity to perform high-
intensity exercise. On the contrary, Koh et al. [179] examined the responses of blood 
lipids and lipoproteins to extended-release niacin and exercise. They concluded that the 
combined effects of extended-release niacin and a single bout of exercise did not provide 
a synergistic effect on blood lipids and lipoproteins. Based on the literature, the doses 
used in our study would seemingly have little to no ergogenic effect. 
Mucuna Pruriens 
In this study, we planned to use 1g/day and 1.5g/day Mucuna pruriens in two 
doses of PWS. L-DOPA (L-3,4-dihydroxyphenylalanine), found within the seeds of 
Mucuna pruriens, is a naturally occurring non-protein amino acid, synthesized from L-
 35 
 
 
tyrosine. The most important function of L-DOPA is to act as the precursor to the 
neurotransmitter dopamine, as well as the catecholamines epinephrine and 
norepinephrine [180]. Mucuna pruriens is recognized as an aphrodisiac, and has been 
shown to improve mental alertness and coordination [181]. Shah and Goyal [182] 
investigated the neuropsychopharmacological effect of a polyherbal formulation 
supplement containing Mucuna pruriens and other ingredients (500mg/kg) on learning 
and memory processes in rats. The supplement activity on memory acquisition and 
retention was studied using passive avoidance learning and elevated plus maze model. 
The animals treated with polyherbal formulation supplement showed a significant 
decrease in transfer latency as compared to the control group. Polyherbal formulation 
supplement also produced significant improvement in passive avoidance acquisition and 
memory retrieval, as compared to the controls and reduced the latency to reach the shock 
free zone after 24 hours. The authors found that the supplement resulted in significant 
improvement in passive avoidance acquisition and memory retrieval in rats. Based on 
the literature, Mucuna pruriens supplementation at doses used in our study would 
seemingly have little to no effect on cognitive function. 
Vitamin B6 
In this study, we planned to use 1.48mg/day and 2mg/day vitamin B6 in two 
doses of PWS. Vitamin B6 refers to all biologically active forms of vitamin B6. The 
forms include pyridoxine, pyridoxal, pyridoxamine, pyridoxine phosphate, pyridoxal 
phosphate, and pyridoxamine phosphate. Of those, pyridoxine, pyridoxal, and 
pyridoxamine are the most common forms in foods [183]. A major function of vitamin 
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B6 is the metabolism of proteins and amino acids. The most biologically active form of 
vitamin B6 is pyridoxal 5’-phosphate which acts as a cofactor for transaminases, 
decarboxylases, and other enzymes used in the metabolic transformations of amino acids 
and nitrogen-containing compounds. During exercise, the gluconeogenic process 
involves the breakdown of amino acids for energy in the muscle and the conversion of 
lactic acid to glucose in the liver. Various pyridoxal 5’-phosphate-containing enzymes 
are involved in this metabolically driven conversion [184, 185]. Few studies have 
examined the vitamin B6 status in athletes. Three studies indicated that 40% to 60% of 
athletes have reduced vitamin B6 based on the enzyme stimulation test [186-188]. Only 
one study reported more than one indicator of B6 nutriture, and it found less (17-35%) 
deficiency among the athletes than when only one indicator of status was used, 
indicating the need to use independent biochemical measures of B6 nutritional status and 
dietary B6 intakes to assess the interaction between diet and performance [186]. Coburn 
et al. [189] examined the influence of dietary B6 in men. The men received a B6-
depletion diet (1.8μM of pyridoxine HCl) for 6 weeks followed by a self-selected diet 
supplemented with 980μM/d of pyridoxine HCl for 6 weeks. Depletion resulted in a 
significant decrease in plasma pyridoxal and pyridoxal phosphate concentrations and a 
significant increase in the enzyme stimulation test. Dietary B6 did not affect muscle 
pyridoxal phosphate. Despite alterations in dietary B6, skeletal muscle concentrations of 
B6 are recalcitrant to depletion and plasma B6 concentrations are a rapidly responding 
pool that may not reflect tissue stores. Based on the literature, vitamin B6 used in our 
study would seemingly have little to no ergogenic effect. 
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Vitamin B9 
In this study, we planned to use 0.5mg/day and 0.76mg/day vitamin B9 in two 
doses of PWS. Vitamin B9 (Folate) serves as a coenzyme in single-carbon transfers in 
the metabolism of nucleic and amino acids. It is required for synthesis of purines and 
pyrimidines that are needed for DNA production and erythropoiesis. A deficiency of 
folate causes abnormal cell replication, particularly in the erythropoietic system, and 
results in megaloblastic anemia. This type of anemia also is caused by vitamin B12 
deficiency. Supplemental folate in the presence of B12 deficiency can correct 
megaloblastic anemia but not the B12 deficiency [190, 191]. Singh et al. [192] found 
adequate serum folate concentrations in ultra-marathoners. Folate supplementation of 
folate-deficient, but not anemic, athletes did not improve physical performance. Female 
marathoners with low serum folate concentrations (<4.5ng/mL) supplemented with 
folate (5mg/day for 10 weeks) did not experience a significant improvement in treadmill 
performance, cardiorespiratory function, or metabolic response during exercise as 
compared to PLA treated, folate-depleted controls [193]. The lack of a physiologic 
benefit of folate supplementation contrasted with a significant increase in serum folate. 
Thus, changes in circulating folate may not reflect changes in tissue or cellular folate 
status [183]. Based on the literature, vitamin B9 used in our study would seemingly have 
little to no ergogenic effect. 
Vitamin B12 
In this study, we planned to use 1.8mg/day and 2mg/day vitamin B12 in two 
doses of PWS. Vitamin B12 (Cyanocobalamin) is a general term that describes a group of 
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cobalt-containing compounds, the corrinoids. This vitamin contains cobalamin with or 
without a cyanide group, both of which are biologically active for humans. 
Cyanocobalamin acts as a coenzyme for the methyl transfer reaction that converts 
homocysteine to methionine and another reaction that converts L-methyl-malonyl 
coenzyme A to succinyl coenzyme A. It also is required for normal erythrocyte 
production and neurologic function [191]. Cyanocobalamin is involved in carbohydrate 
metabolism and maintaining nerve cell transmission which is fundamental for muscle 
contraction, coordination, and muscle growth. In addition, cyanocobalamin is involved 
in the metabolism of every cell in the body, especially affecting DNA synthesis and 
regulation, fatty acid synthesis and energy production [194]. General cyanocobalamin 
supplementation apparently has no beneficial effect on performance. In well-nourished 
athletes, no ergogenic effect has been reported. Based on the literature, vitamin B12 used 
in our study would seemingly have little to no ergogenic effect. 
Vitamin C 
In this study, we planned to use 500mg/day and 760mg/day vitamin C in two 
doses of PWS. Vitamin C (ascorbic acid) is a micronutrient with numerous crucial 
physiological functions and acts well in the aqueous environment. It is found in high 
contents in leukocytes, adrenal and pituitary glands. In addition to scavenging of free 
radicals, vitamin C recycles the tocopherol radical, thereby being reduced to 
dehydroascorbic acid that can be regenerated, for example by glutathione-glutathione 
reductase system. This vitamin is also an enzyme cofactor in the biosynthesis of 
carnitine, histamine, collagen, norepinephrine, and epinephrine [195-197]. Some decades 
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ago, the intake of vitamin C was inefficient; however, nowadays, vitamin C intake has 
increased due to the abundance of fruits and vegetables. Vitamin C is enriched in every 
food, particularly meat-containing foods as antioxidant [198]. Pharmacokinetic data 
indicate a plasma steady state after the ingestion of 200mg vitamin C, whereas ascorbic 
acid contents of neutrophils, monocytes, and lymphocytes are saturated at a daily intake 
of 100mg [199]. Ascorbic acid has a multiplicity of antioxidant properties, but the high 
dose supplementation can exert pro-oxidant effects in vitro, usually by interaction with 
transition metal ions [200]. Based on the literature, vitamin C used in our study would 
seemingly have little to no ergogenic effect. 
Summary 
As it has been discussed, PWS supplementation is a relatively recent and 
growing area of research. PWS has shown to cause beneficial effects on cognitive 
function and high intensity exercise including anaerobic sprints and resistance training. 
Over time, these improvements could potentially increase training adaptations; future 
studies will assist further explanation of the precise effects of PWS and ED to increase 
alertness as well as improvement in athletic performance under a variety of conditions in 
both men and women. The main body of research has focused on the effects of either 
individual PWS or those containing a few ingredients in young athletes. It seems that 
studying the effects of multi-ingredient PWS can potentially open the door to more 
research of the effects in athletes. The two doses of PWS used in the present study 
contain caffeine and nitrate likely to affect cognitive and/or exercise performance. Other 
ingredients used in the supplement were lower than those recommended in previous 
 40 
 
 
studies. Rather than offering a watered down product, the supplement provider company 
tries to realize if their product functions in light of having to make business/economic 
decisions on cost to benefit return ratios. Further research in the area of multi-ingredient 
PWS and ED may potentially promote more improvements in high intensity exercise, 
sport performance, and cognitive function in a wide range of individuals. 
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CHAPTER III  
METHODS 
Experimental Design  
Table 3.1 presents the experimental design of the study and what was required by 
participants during each testing session throughout the 35 days. Participants repeated the 
sessions two times after 1-week washout while randomly ingesting the alternate 
supplements. Figure 3.1 outlines an individual testing session within the study. In a 
randomized, double-blind, placebo-controlled trial and cross-over manner, we examined 
the acute and after 7 days effects of consuming PWS containing caffeine, Cr nitrate, β-
alanine, arginine α-ketoglutarate, N-acetyl tyrosine, Mucuna pruriens, and ascorbic acid, 
at two doses on cognitive function and exercise performance. The independent variable 
was the nutritional supplementation. The outcome variables were exercise performance 
including upper body and lower strength, and anaerobic power; resting energy 
expenditure responses; heart rate and blood pressure; readiness to perform; cognitive 
function; hematologic variables; general health markers; and side effect questionnaires.  
Study Site 
All laboratory testing took place in the Exercise & Sport Nutrition Laboratory. 
This laboratory is located in the Department of Health and Kinesiology and College of 
Education and Human Development at Texas A&M University in College Station, 
Texas. 
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Table 3.1 Experimental Design 
 
 
Familiarization 
Session 
Day 0 Day 2 Day 4 Day 7 
Physical Exam 
Body Weight 
Body 
Composition  
1RMa 
Determination on 
the Bench Press 
and Leg Press 
Anaerobic Sprint 
Practice Test  
Schedule Testing 
Refrain from 
exercise, caffeine 
and use of over-
the-counter 
stimulants for 
48-hours and 
fasted for 12 
hours prior to 
days 0 and 7 
testing sessions 
 
 
 
Fasting Blood Sample 
Resting HRb/BPc/ECGd – 5 
min.; start REE (0 min.) 
Ingest supplement in a 
randomized and 
counterbalanced manner (30 
min.) 
Stop REEe (60 min.) 
Stroop Word & Color Test 
Ready to Perform VASf 
Sleep Quality and 
Caffeine Questionnaires 
Resting HR/BP/ECG/BIAg – 5 
min. 
Bench Press Warm-Up 
Bench Press (3 sets of 10 reps 
@ 70% of 1RM with 2-min rest 
btw. sets.  Total reps to failure 
on last set) 
Resting HR/BP – 1 min after 
bench press 
5 min. rest 
Leg Press Warm-up 
Leg Press (3 sets of 10 reps @ 
70% of 1RM with 2-min rest 
btw. sets. Total reps to failure on 
last set) 
Resting HR/BP – 1 min after leg 
press 
5 min. rest 
Wingate Anaerobic Capacity 
Test 
Resting HR/BP – 1 min after 
Wingate test 
Ingesting supplement for six 
additional days 
Stroop Word 
& Color Test 
Ready to 
Perform VAS 
Sleep Quality 
and 
Caffeine 
Questionnaire 
Stroop Word 
& Color Test 
Ready to 
Perform VAS 
Sleep Quality 
and 
Caffeine 
Questionnaire 
Fasting Blood Sample 
Resting HR/BP/ECG – 5 min.; 
start REE (0 min.) 
Ingest supplement in a 
randomized and 
counterbalanced manner (30 
min.) 
Stop REE (60 min.) 
Stroop Word & Color Test 
Ready to Perform VAS 
Sleep Quality and 
Caffeine Questionnaires 
Resting HR/BP/ECG/BIA – 5 
min. 
Bench Press Warm-Up 
Bench Press (3 sets of 10 reps 
@ 70% of 1RM with 2-min rest 
btw. sets.  Total reps to failure 
on last set) 
Resting HR/BP – 1 min after 
bench press 
5 min. rest 
Leg Press Warm-up 
Leg Press (3 sets of 10 reps @ 
70% of 1RM with 2-min rest 
btw. sets. Total reps to failure 
on last set) 
Resting HR/BP – 1 min after leg 
press 
5 min. rest 
Wingate Anaerobic Capacity 
Test 
Resting HR/BP – 1 min after 
Wingate test 
4 – Day Food Record-One week 
washout 
a 1-Repetition Maximum, b Heart rate, c Blood pressure, d Electrocardiogram, e Resting Energy Expenditure, f Visual Analogue 
Scale,  
g Bioelectrical Impedance Analyzer 
 43 
 
 
Recruiting Methods 
Recruitment fliers were posted around the Health & Kinesiology building as well 
as emailed to students enrolled in physical education activity classes. People expressing 
interest in the study were interviewed via phone screening or by on-site attendance to 
determine if they were qualified to participate. All eligible subjects participated in a 
morning FAM session with the investigator during which the study design, testing 
procedures, and supplementation protocols were explained in detail. This included a 
brief description of the blood collection procedure and a brief explanation of the tests 
 
 
 
 
 
 
 
 
 
 
 
 
and equipment that were used. Information related to dietary records and side effect 
questionnaires were also explained during the FAM session. Subjects meeting all criteria 
were asked to sign an informed consent approved by the Institutional Review Board of 
Texas A & M University (College Station, TX, IRB number: IRB2014-0795). They were 
also asked to fill out a medical history questionnaire to eliminate those with any possible 
Figure 3.1 Testing Session Timeline 
 44 
 
 
contraindications to participate in the study. A research nurse reviewed medical history 
documents and performed a physical exam on each subject to ensure safety and 
participation eligibility. Participants were asked to continue their training without 
initiating any new exercise or diet regime. They were weighed and assessed for body 
mass, BP, HR, and dual energy X-ray absorptiometry (DXA) body composition 
(excluding cranium). Then, participants performed a 1RM test on the bench press and 
leg press. Finally, participants performed a Wingate 30 sec anaerobic capacity test on a 
cycle ergometer. Following baseline measurements, participants were randomly assigned 
into three treatments. At the end of the session, participants were scheduled to return to 
the lab for the first week of supplementation. 
Inclusion and Exclusion Criteria 
Participants were allowed to take part in the study if they were between the ages 
of 18-40 and if they had at least six months immediate prior history of resistance training 
including bench press and leg press/squat. The exclusion criteria of the study were a 
history of treatment for metabolic disease (e.g., diabetes); hypertension; hypotension; 
thyroid disease; symptomatic arrhythmias and/or cardiovascular disease; current use of 
any prescription medication; intolerance to caffeine and/or other natural stimulants; 
pregnant or lactating females; a history of smoking; or excessive drinking (>12 drinks 
per week).  
Procedures 
Participants reported to the lab for day 0 and day 0 testing after a 12-hr fast and 
refrained from exercise training and ingestion of caffeine and over the counter 
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medication with a known stimulant use for 48 hrs prior to testing sessions. All testing 
sessions were started in the morning. Participants were instructed to maintain their 
normal resistance training program on study day where physical activity was not 
restricted (e.g. 48-hrs prior to each long testing session). Participants were also asked to 
not change their current diet level during the course of the study. Participants recorded 
their dietary intake prior to each supplementation week. Once at the lab, participants 
turned in their food records. Next, they donated approximately 20ml of unsupplemented 
and fasting blood sample via venipuncture. Then, body mass was measured and 
participants were assessed for HR, BP, and resting energy expenditure (REE) for two 
separate 30-min periods. Following the first 30-min, the REE measurement participants 
ingested their assigned supplement. Then, REE measurement continued for another 30 
min. Resting HR were measured immediately prior to REE and every 10 min during the 
REE measurement. Then, HR was measured 1 min after bench press test, 1 min after leg 
press test, and 1 min after Wingate anaerobic power test. Resting BP was measured prior 
to and following REE. BP was also be measured immediately after determining HR at 
the end of each exercise test. 
Upon supplementation, participants continued the REE for another 30 min. 
Following REE measurement, participants performed a series of cognitive function tests 
as well as readiness to perform, sleep quality, and caffeine questionnaires using VAS. 
Participants then warmed up for 5 min and performed three sets of 10 repetitions at 70% 
of 1RM on the bench press and leg press with 2 min recovery between sets and 5 min 
recovery from exercise modes. Participants performed as many repetitions as possible 
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during the last set. Then, they performed a 30 sec anaerobic capacity test on a cycle 
ergometer. Participants were asked to pedal as fast as possible prior to application of the 
workload and sprint at an all-out maximal capacity for 30-sec Wingate test.  
Supplementation Protocol 
Participants were matched for age, body mass, and FFM and randomly assigned 
to ingest in a double-blind cross-over manner either: (1) flavored dextrose PLA (12g); 
(2) PWS [caffeine (300mg), creatine nitrate in a 2:1 ratio as a salt (2.0g), β-alanine 
(3.2g), arginine α-ketoglutarate (2.0g), N-acetyl tyrosine (300mg), Mucuna pruriens 
(1.0g), ascorbic acid (500mg), dextrose (2.6g) (Table 3.2)]; (3) PWS at ~150% dosage 
(PWS150) (Table 3.3) (Cellucor®, Woodbolt International, Bryan, TX). In order to 
balance the 150% dosage, 2.6g dextrose PLA was added. Participants were required oral 
administration of one serving of the supplement mixed in approximately eight ounces of 
plain water. Supplements were provided by the funding agency, and were independently 
packaged into coded single foil packets for double-blind administration following Good 
Manufacturing Practices and certified to contain the aforementioned ingredients by VMI 
Nutrition (Salt Lake, UT). All supplements had similar color and powdered texture. 
Participants were instructed to ingest one foil packet per day immediately prior to 
exercise on training days and around noon on non-training days. On testing days, 
ingesting followed after 30 min REE measurement. Supplement compliance was verified 
by weekly compliance verification and collecting and counting empty packets. 
Participants repeated the experiment after a one week washout period for two more times 
with alternate supplements in a randomized manner. 
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Table 3.2 PWS Preworkout Supplement Ingredients and Dosages 
PWS Formula G mg 
β-Alanine 3.2 3,200 
Arginine AKG 1 2:1 2.0 2,000 
Creatine Nitrate (1.34g CR; 0.66g N) 2.0 2,000 
Ascorbic Acid  0.5 500 
N-Acetyl Tyrosine  0.3 300 
Caffeine Anhydrous 0.3 300 
Mucuna Pruriens 15% L-Dopa 2 1.0 1,000 
Niacinamide USP 3 0.06 60 
Theacrine 0.01 10 
Pyridoxal 5-Phosphate 0.00148 1.48 
Folic Acid USP 0.0005 0.5 
Methylcobalamin  0.0018 1.8 
Dextrose 2.62 2,620 
TOTALS 12 12,000 
1. α-ketoglutarate 
2. L-3,4-dihydroxyphenylalanine 
3. The United States Pharmacopeia 
 
 
 
Table 3.3 PWS150 Preworkout Supplement Ingredients and Dosages 
 
PWS150 Formula G mg 
β-Alanine 4.8 4,800 
Arginine AKG 1 2:1 3.0 3,000 
Creatine Nitrate (2.01g CR; 0.99g N) 3.0 3,000 
Ascorbic Acid  0.76 760 
N-Acetyl Tyrosine  0.46 460 
Caffeine Anhydrous 0.4 400 
Mucuna Pruriens 15% L-Dopa 2 1.5 1,500 
Niacinamide USP 3 0.09 90 
Purenergy™ (43%) caffeine (12mg), (57%) 
pterostilbene (12.5mg) 
0.05 50 
Theacrine 0.02 20 
Pyridoxal 5-Phosphate  0.002 2.0 
Folic Acid USP 0.00076 0.76 
Methylcobalamin  0.002 2.0 
TOTALS 14 14,000 
1. α-ketoglutarate 
2. L-3,4-dihydroxyphenylalanine 
3. The United States Pharmacopeia 
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Dietary Recording and Analysis  
After the FAM session and prior to day 0 testing, participants completed a 
dietary record to include three weekdays and one weekend day. Participants were asked 
to precisely record all the food item (brand if applicable), preparation method, and total 
quantity consumed as well as beverage consumption except water. The next two dietary 
recordings then took place during the washout period prior to each supplementation 
week. All food logs were entered and analyzed by a registered dietitian using dietary 
analysis software (ESHA Food Processor Version 8.6, Salem, OR, USA). Appendix D 
shows the daily food-log table. 
Body Composition Testing  
 Height and body mass were measured according to standard procedures using a 
self-calibrating electronic scale (Cardinal Detecto Scale Model 8430, Webb City, MO) in 
socks or bare feet with an accuracy of ±0.02 kg and ±0.25 cm, respectively. Total body 
water was determined at day 0 and day 7 testing sessions under standardized conditions 
using an ImpediMed DF50 bioelectrical impedance analyzer (BIA, ImpediMed, San 
Diego, CA, USA). Participants were stationed in a supine position with four electrodes 
placed on the wrists and ankles. Bioelectrical impedance analysis has been shown to be a 
valid method to determine total body water, intracellular water, and extracellular water 
[201, 202]. Body composition testing took place once at the FAM session. Body 
composition was measured by Hologic Discovery DXA technology (Hologic Inc., 
Waltham, MA, USA) equipped with APEX. Software (APEX Corporation Software, 
Pittsburg, PA, USA). Previous studies indicate DXA to be an accurate and reliable 
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means to assess changes in body composition [203, 204]. Participants were asked to 
remove all metal from their bodies or clothing, including items such as jewelry and body 
piercings. The existence of any metal on a person may interfere with the accuracy of the 
DXA scan, although the extent of this error is unknown. Participants were then 
positioned in the supine position based on manufacturer’s guidelines by a trained 
technician. DXA measurement was then performed, taking approximately 6-8 min. 
Analysis of body composition was immediately performed by a trained technician to 
determine body composition. Test/retest reliability studies performed on male and 
female athletes with DXA yielded mean deviation for total bone mineral content and 
total fat-free/soft tissue mass of 0.31-0.45%, with a mean intra-class correlation of 0.985 
[203].  
Resting Energy Expenditure Measurement 
REE was measured by indirect calorimetry using a ParvoMedics TrueOne 2400 
Metabolic Measurement System (ParvoMedics, Inc., Sandy, UT). A large plastic 
“bubble” was placed over the participant’s head while a plastic sheet covers the 
participant’s upper body, preventing external air from entering the bubble. Oxygen flows 
into the bubble from a valve at the top. The calorimeter measures the amount of O2 
consumed ( O2) and the amount of CO2 produced ( CO2) while at rest by comparing 
the concentrations of O2 and CO2 in the air inspired by the participant with the 
concentration in the air expired by the participant. 
The participant lied on his/her back on the bed for 30 min pre- and 30 min post-
ingestion. The 1-hr REE measurement was conducted in order to assess the plausible 
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changes in O2, CO2, and respiratory exchange ratio (RER) following 
supplementation. The participant relaxed but not fall to sleep during the measurement. 
The lab technicians looked in from time to time to make sure he/she is awake. The 
participant was free to remove the bubble if he/she felt uncomfortable. 
Heart Rate Measurement  
During the testing sessions, participants were assessed for several HR 
measurements. HR was measured in two forms: resting electrocardiographs (ECG) and 
resting HR using pulse palpation. Resting ECG was assessed using a CARDIO System 
12-lead interpretative ECG (Nasiff Associates, Inc., Brewerton, NY). HR was also 
measured by palpitation of the radial artery using standard procedure in the seated 
position [205]. Trained technicians were count the pulse for 15 sec to determine the 
number of beats per minute. 
Blood Pressure Measurement  
BP was determined at each time point by auscultation of the brachial artery using 
a mercurial sphygmomanometer using standard clinical procedure [206]. This proceeded 
immediately after determining HR. The BP measurement was performed before, during, 
and after 60 min REE measurement as well as following Stroop Color test in the supine 
position. The remaining BP measurements occurred in the seated position 1 min after 
each exercise test. 
Cognitive Function (Stroop Word-Color Test) 
The cognitive function was tested by Stroop Word-Color test which was 
standardized by Golden and others [207-209]. The test consists of three pages (Appendix 
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E). Each page contains 100 items, presented in 5 columns of 20 items. Items on Page 1 
(Word) are the color words RED, GREEN, and BLUE in black ink. On Page 2 (Color) 
the items are XXX’s colored in red, green, or blue ink. Items on Page 3 (Word-Color) 
are the words RED, GREEN, and BLUE printed in red, green, or blue ink with the 
limitation that word and ink do not match. Participants read loudly each page (Word, 
Color, and Word-Color page in order) for 45 sec as fast as they can. The number of 
correct responses obtained during the time period is used to assess cognitive function. In 
neuropsychology, Stroop Word-Color test measures three basic domains. Word 
measures post left hemisphere function and reading skills. The Color section determines 
disorders of the dominant temporal-occipital areas of the posterior right hemisphere. The 
Word-Color section measures prefrontal cortex, executive functions [210, 211]. Day-to-
day test reliability of administering this test in our lab has yielded a standard error of 
mean (SEM) ranging from 1.8-1.86 counts, an SEM as a percent of grand mean ranging 
from 2-3%, coefficient of variation (CV) ranging from 0.14-0.25, and intraclass 
correlation coefficients of 0.90, 0.68, 0.57 for Word, Color and Word-Color, 
respectively. Jensen [212] reported test/retest reliabilities of 0.88, 0.79, and 0.71 for the 
three Word, Color, and Word-Color raw scores. Golden [213] reported test-retest 
reliabilities of 0.86, 0.82, and 0.73 for the individual version. As can be seen, there are 
little differences between these correlations, despite using different forms of test. 
Readiness to Perform Visual Analogue Scale 
Readiness to Perform was measured by VAS with five subjective feeling 
(strongly disagree to strongly agree) on 20 cm dotted bar (Appendix F). The VAS has 
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five questions; (1) “I am looking forward to today’s workout”, (2) “I am optimistic about 
my future performance”, (3) “I feel vigorous and energetic”, (4) “My appetite is great”, 
(5) “I have little muscle soreness”. Participants circled the number or dotted between 
numbers that best indicated how they currently feel. Day-to-day test reliability of 
administering this test in our lab has yielded a SEM’s ranging from 0.9-0.13, an SEM as 
a percent of grand mean ranging from 2-4%, CV’s ranging from 0.19-0.34, and 
intraclass correlation coefficients of 0.66, 0.88, 0.70, 0.90, and 0.67 for questions 1 
through 5, respectively.   
Sleep Quality and Caffeine Ingestion Assessment  
Participants were also given a short sleep quality questionnaire (SQQ) (Appendix 
G) at each testing session to determine how well they tolerated supplementation; and if 
they experienced any symptoms as a result of the supplement. The SQQ is an effective 
instrument that was used to measure the quality and patterns of sleep in participants. It 
differentiates “poor” from “good” sleep quality by measuring several areas 
(components): sleep duration, subjective sleep quality, enthusiasm quality, and sleep 
disturbances over the past 48 hrs. The SQQ also contains a 10-item “yes” or “no” 
question regarding the probable sleeping troubles for the past 48 hrs: cannot get to sleep 
within 30 min, wake up in the middle of the night or early morning, have to get up to use 
the bathroom, cannot breathe comfortably, cough or snore loudly, feel too cold, feel too 
hot, had bad dreams, have pain, and other reasons. Day-to-day variability in SQQ in our 
lab yielded an SEM of 0.38, an SEM as a percent of grand mean of 8.2%, a CV range of 
0.22-2.2, and an intraclass correlation coefficient range of -1.3-0.92.    
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Participants were also be given a caffeine questionnaire (CQ) (Appendix H) at 
each testing session and they were asked to rank the severity of their symptoms - 
drowsiness, tiredness, irritability, etc. Participants were asked to rank their symptoms 
with 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a bit), and 4 (extremely). During 
day 0 and day 7 testing sessions, the questionnaires were completed immediately after 
the REE measurement. In addition, participants referred to the lab for two screening 
sessions to complete the questionnaires during the supplementation week. Day-to-day 
variability in caffeine inventory questions in our lab yielded an SEM of 0.02, an SEM as 
a percent of grand mean of 2.5%, a CV range of 0.22-5.2, and an intraclass correlation 
coefficient range of -0.2-0.88.   
Strength Testing with 1RM 
Maximal strength was determined following a standard warm-up consisting of 10 
repetitions using 50% of their estimated 1RM, 5 repetitions using 70% of their estimated 
1RM, and 1 repetition using 90% of their estimated 1RM. Participants continued 
increasing weight until their 1RM’s were determined. Participants were encouraged to 
reach 1RM during the FAM trials. With 1RM that was determined at the FAM session, 
participants performed three sets of bench and leg press test. At the first and second sets, 
participants were required to lift 10 repetitions at 70% of 1RM on the bench press and 
leg press interspersed by 2-min of rest between sets and 5-min recovery between each 
exercise testing modality. During the third set, we asked participants to complete as 
many repetitions as possible. Total lifting volume was calculated by multiplying the 
amount of weight lifted times the number of successful repetitions completed. The 
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concurrent verbal encouragement was applied during the tests as an extrinsic 
motivational factor to encourage maximal performance. All strength testing took place 
on an isotonic Olympic bench press and hip/leg sled (Nebula Fitness, Versailles, OH) 
using standard procedures [214]. Upper body power output was measured using a Tendo 
Fitrodyne (Tendo Sport Machines, Slovak Republic). Tendo Power Analyzer is a 
portable training tool that determines power output and bar speed in training and testing. 
Peak power, average power, and average velocity were measured during each repetition 
of the three sets. Day-to-day test reliability of performing this endurance test in our lab 
on resistance-trained participants has yielded a standard error of measurement (SEM) of 
86 kg, a SEM as a percent of grand mean of 4%, a CV of 0.34, and an intraclass 
correlation coefficient of 0.99 for 3 sets of bench press total lifting volume and an SEM 
of 480 kg, an SEM as a percent of grand mean of 4%, a CV of 0.32, and an intraclass 
correlation coefficient of 0.96 for 3 sets of leg press total lifting volume. 
Wingate Anaerobic Capacity Test 
The Wingate test requires the participant to pedal a mechanically braked bicycle 
ergometer for 30 sec, at an "all out" pace. Wingate testing was assessed using a Lode 
Excalibur Sport Ergometer (Lode BV, Groningen, The Netherlands) and work rate was 
set at of 7.5 J/kg/rev for everyone. Participants were asked to pedal as fast as possible 10 
sec prior to application of the workload and sprint at an all-out maximal capacity for 30-
sec Wingate test. The concurrent verbal encouragement was applied during the test as an 
extrinsic motivational factor to encourage maximal performance. Day-to-day variability 
in performing Wingate anaerobic capacity tests in our laboratory yielded an SEM of 18 
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W, an SEM as a percent of grand mean of 3%, a CV 0.26, and an intraclass correlation 
coefficient of 0.89 for mean power.    
Blood Collection 
Participants refrained from exercise, caffeine, and use of over-the-counter 
stimulants 48 hrs prior to days 0 and 7 testing sessions. They were required to be fasted 
for 12 hrs prior to donating approximately 20mL of venous blood from an antecubital 
vein in the forearm according to standard phlebotomy procedures. Blood sample was 
collected via venipuncture (catheterization) in two 7.5mL BD Vacutainer® serum 
separation tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), leave at 
room temperature for 15 min, and then was centrifuged at 3500 rpm for 10 min using a 
standard, refrigerated (4°C) bench top Thermo Scientific Heraeus MegaFuge 40R 
Centrifuge (Thermo Electron North America LLC, West Palm Beach, FL, USA). Serum 
supernatant was removed and stored at -80°C in polypropylene microcentrifuge tubes for 
later analysis. Serum was analyzed for liver enzymes including alkaline phosphatase 
(ALP), AST, and alanine transaminase (ALT); kidney enzymes including creatinine and 
blood urea nitrogen (BUN); muscle enzymes including CK and LDH; glucose; and 
blood lipids including total cholesterol (TC), high density lipoprotein (HDL), low 
density lipoprotein (LDL), and triglycerides (TG) using a Cobas® C 111 (Roche 
Diagnostics, Basel, Switzerland). Calorimetric assay kits were used to measure serum 
creatine concentrations (Sigma-Aldrich, St. Louis, MO). The Cobas® automated clinical 
chemistry analyzer was calibrated according to manufacturer guidelines. This analyzer 
has been known to be highly valid and reliable in previously published studies [215]. 
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The internal quality control for the Cobas c 111 was performed using two levels 
of control fluids purchased from manufacturer to calibrate acceptable SD and 
coefficients of variation values for all aforementioned assays. Samples were re-run if the 
observed values were outside control values and/or clinical norms according to standard 
procedures. Test-to-test reliability (10-days) assessment of assays evaluated in this study 
yielded reliability CV’s ranging 0.4–2.4% for low control samples and 0.6-1.9% for high 
controls with precision ranging 0.8–2.4% on low and 0.5–1.7% for high controls.       
Blood was also collected in a single 3.5mL BD Vacutainer® lavender top tube 
containing K2 EDTA (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), leave 
at room temperature for 15 min, and  was refrigerated for approximately 3-4 hrs before 
complete blood count analysis. Complete blood count with platelet differential was run 
on whole blood [hemoglobin, hematocrit, red blood cell (RBC) counts], mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), red cell distribution width (RCDW), white blood 
cell counts, lymphocytes, granulocytes, and mid-range absolute count (MID) using a 
Abbott Cell Dyn 1800 (Abbott Laboratories, Abbott Park, IL, USA) automated 
hematology analyzer. The internal quality control for the Abbott Cell Dyn 1800 was 
performed using three levels of control fluids purchased from manufacturer to calibrate 
acceptable CV values for all whole blood cell parameters (±6.3%). 
Statistical Analysis  
All data were analyzed using a repeated measured multivariate analysis of 
variance (MANOVA) with Wilks’ Lambda and Green-Geisser adjustments using SPSS 
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24.0 for Windows (IBM Corporation, Armonk, NY, USA). Participant baseline 
demographic data were analyzed using one-way ANOVA. Overall MANOVA effects 
were examined as well as MANOVA univariate treatment effects for certain variables 
when significant interactions were seen. Greenhouse-Geisser univariate tests of time, 
treatment and treatment x time effects were reported for each variable analyzed within 
the MANOVA model. Data were considered statistically significant when the probability 
of error is 0.05 or less. Post-hoc LSD pairwise comparisons using partial eta squared was 
used to determine effect magnitude. In REE, area under the curve (AUC) of O2, CO2, 
and REE were calculated by summing up response by every 1-min for 30-min pre and 
30-min post-ingestion of supplement. AUC was computed on REE data by GraphPad 
Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA) calculating the trapezoid 
rule and analyzed by ANOVA. In addition, 95% confidence intervals was constructed 
for Stroop Word/Color test, readiness to perform VAS, and exercise outcomes. When the 
95% confidence interval did not include zero, the change was considered significant (p < 
0.05) [216]. Regarding Stroop test and VAS results, the baseline values were considered 
as covariates. Delta and percent change values were calculated and used to determine 
changes from day 0 which were analyzed by repeated measures analysis of variance 
(ANOVA). In regard to hematology, we also pursued analyses denoting changes from 
normal to exceeding normal clinical limits from day 0 to day 7 using a Chi-square 
analysis. With regard to SQQ, we used Cochran's Q test to determine if there are 
differences on a dichotomous dependent variable among three treatments.
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CHAPTER IV  
RESULTS 
Subject Demographics  
Figure 4.1 presents a CONSORT schematic for study participation. Twenty two 
participants were initially recruited for the current study, all completed consent forms 
and participated in the required familiarization session. However, of the original 22 
participants, 19 completed the study (16 men and 3 women). One participant dropped 
out due to time constraints and two participants could not continue the study, because 
ingesting PWS150 resulted in jittery and lightheadedness. The baseline demographics 
for the participants are listed in Table 4.1. We did not observe any significant changes in 
body weight and hydration status during the course of study (p > 0.05) (Table 4.2).  
Diet 
Table 4.3 presents absolute and relative macronutrient intake data. MANOVA 
analysis revealed overall Wilks’ Lambda treatment (p = 0.95). One-way ANOVA did 
not reveal any statistically significant differences among dietary intake from session to 
session of testing (p > 0.05).   
Resting Energy Expenditure 
Figures 4.2, 4.3, 4.4, and 4.5 present the day 0 and day 7 minute-by-minute 
comparison of (a) O2, (b) CO2, and (c) RER for 30-min pre- and 30-min post 
supplementation. Table 4.4 presents the results for O2, CO2, RER, and REE before 
and after supplementation. MANOVA analysis revealed overall Wilks' Lambda
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Table 4.1 Participant Demographics 
N 
Age  
(yrs) 
Height 
(cm) 
Body Weight  
(kg) 
BMI 
Body Fat 
(%) 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
19 21.8 ± 2.1 175.7 ± 9.5 83.9 ± 18.2 27.1 ± 3.9 21.6 ± 8.5 
Values are means ± standard deviations (SD). Data were analyzed by one-way ANOVA. 
 
 
treatment x time (p = 0.76). There were no significant changes for O2 (p = 0.15), CO2 
(p = 0.08, partial η2 = 0.07 – medium effect), RER (p = 0.24), and REE (p = 0.61). Table 
4.5 presents the AUC results for O2, CO2, RER, and REE before and after 
supplementation. The AUC did not show any significant interaction for REE 
 
Figure 4.1 Consort Diagram for Study Participation 
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Table 4.2 Body Weight and Hydration Status 
Variable Treatment Day 0 Day 7    
    Mean ± SD Mean ± SD Mean ± SE   p-level 
Body Weight PLA 83.5 ± 18.1 83.8 ± 17.9 83.7 ± 2.8 Treatment 0.99 
(kg) PWS 83.8 ± 17.9 84.1 ± 17.9 84.0 ± 2.8 Time 0.08 
 
PWS150 84.2 ± 18.3 84.3 ± 18.3 84.3 ± 2.9 T x T 0.51 
 Overall 83.9 ± 17.8 84.1 ± 17.7    
Total Body Water PLA 38.8 ± 6.0  39.9 ± 5.9 39.3 ± 0.9 Treatment 0.83 
(L) PWS 40.8 ± 7.9 39.9 ± 6.2 40.3 ± 1.1 Time 0.75 
 
PWS150 40.4 ± 7.9 40.7 ± 7.3 40.6 ± 1.2 T x T 0.25 
 Overall 40.0 ± 7.2 40.2 ± 6.4    
Intracellular Body 
Water (L) 
PLA 22.4 ± 3.3 22.7 ± 3.2 22.5 ± 0.5 Treatment 0.48 
 PWS 24.4 ± 8.2 22.7 ± 3.4 23.6 ± 1.0 Time 0.42 
 
PWS150 22.2 ± 3.5 21.9 ± 3.6 22.1 ± 0.5 T x T 0.44 
 Overall 23.0 ± 5.5 22.4 ± 3.3    
Extracellular Body 
Water (L) 
PLA 17.4 ± 4.3 17.2 ± 3.5 17.3 ± 0.6 Treatment 0.99 
 PWS 17.4 ± 3.8 17.1 ± 3.6 17.2 ± 0.6 Time 1.0 
 PWS150 17.1 ± 3.9 17.7 ± 4.2 17.4 ± 0.6 T x T 0.46 
 Overall 17.3 ± 4.0 17.3 ± 3.7    
Values are means ± standard deviations. Data were analyzed by MANOVA with repeated measures. 
Greenhouse-Geisser Treatment (T), time (T), and Treatment x time (T x T) interaction p-levels are reported 
with univariate treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.80), 
time (p = 0.22), and treatment x time (p = 0.39).   
 
 
 
Table 4.3 Dietary Characteristics 
 Treatment   
               PLA PWS PWS150  Treatment 
Dietary Characteristics Mean ± SD Mean ± SD Mean ± SD Mean ± SE p-level 
Absolute Amount      
Energy Intake (kcals/day) 1,655 ± 230 1,532 ± 232 1,613 ± 282 1,600 ± 33 0.31 
Protein (g) 101.9 ± 27.8 97.3 ± 30.2 101.2 ± 28.3 100.1 ± 3.7  0.87 
Fat (g) 59.2 ± 13.1 52.6 ± 12.5 59.8 ± 15.0 57.2 ± 1.8 0.20 
Carbohydrate (g) 160.4 ± 36.0 152.1 ± 39.5 152.2 ± 48.0 154.9 ± 5.4 0.77 
Relative Amount      
Energy Intake (kcals/kg/day) 20.2 ± 3.4 18.9 ± 4.2 19.9 ± 4.7 19.7 ± 0.5 0.60 
Protein.per.kg 1.26 ± 0.41 1.20 ± 0.43 1.25 ± 0.41 1.24 ± 0.05 0.90 
Fat.per.kg 0.72 ± 0.16 0.66 ± 0.21 0.73 ± 0.22 0.70 ± 0.02 0.44 
Carbohydrate.per.kg 1.95 ± 0.47 1.86 ± 0.51 1.86 ± 0.62 1.89 ± 0.07 0.82 
Values are means ± standard deviations (SD). Differences in macronutrient intake among treatments were tested 
using one-way ANOVA. 
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measurements. The results from the O2, CO2, RER, and REE analysis rejects the 
directional  hypothesis 1 which states that PWS supplementation will increase resting 
energy expenditure. 
Hemodynamic Characteristics  
Table 4.6 presents the results for HR, SBP, and DBP. MANOVA analysis for HR 
and BP revealed Wilks' Lambda treatment x time (p = 0.13). We observed a significant 
interaction for SBP after bench press between PWS and PWS150 at day 0 and between 
PLA and both supplement treatments at day 7 (p = 0.02). The post-bench press SBP 
decreased in PLA, while it increased in PWS and PWS150 treatments. No significant 
interaction was seen for HR (p = 0.08, partial η2 = 0.06 – medium effect) and DBP (p = 
0.49) at day 0 and day 7 for rest and 1 min after each exercise test. The results from Hr 
and BP analysis rejects the directional hypothesis 2 which states that PWS 
supplementation will increase HR and BP responses.  
Readiness to Perform and Cognitive Function  
Readiness to Perform was measured by visual analogue scale with five subjective 
feeling (strongly disagree to strongly agree) on 20 cm dotted bar. The results are 
presented in Table 4.7. MANOVA analysis revealed overall Wilks’ Lambda treatment x 
time (p = 0.36). No significant interactions were observed among treatments regarding 
the perceived readiness to perform as determined by the VAS (p > 0.05). The results 
from readiness to perform analysis rejects the directional hypothesis 3 which states that 
PWS supplementation will improve perceptions of readiness to perform. 
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Figure 4.2 Minute-by Minute Comparison of  O2 Changes During 30-min Pre- and 30-min Post-Supplementation for (a) PLA, (b) PWS, and (c) 
PWS150 Treatments 
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Figure 4.3 Minute-by Minute Comparison of  CO2 Changes during 30-min Pre- and 30-min Post-Supplementation for (a) PLA, (b) PWS, and (c) 
PWS150 Treatments 
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 Figure 4.4 Minute-by Minute Comparison of RER Changes during 30-min Pre- and 30-min Post-Supplementation for (a) PLA, (b) PWS, and (c) 
PWS150 Treatment 
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Figure 4.5 Minute-by Minute Comparison of REE Changes during 30-min Pre- and 30-min Post-Supplementation for (a) PLA, (b) PWS, and (c) 
PWS150 Treatment 
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Table 4.4 REE Measurement Before and After Supplement Ingestion 
Variable Treatment Day 0 Day 0 Day 7 Day 7 
Pre-
Ingestion 
Post-
Ingestion 
Pre-
Ingestion 
Post-
Ingestion 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE p-level 
VO2 PLA 239 ± 56 256 ± 61 244 ± 63 247 ± 58 247 ± 6 Treatment 0.94 
(ml/min) PWS 237 ± 59 253 ± 62 251 ± 59 263 ± 66 250 ± 7 Time 0.002 
PWS150 251 ± 59 270 ± 54 247 ± 51 252 ± 52 252 ± 6 T x T 0.15 
Overall 242 ± 57 260 ± 58* 247 ± 57 254 ± 58* 
VCO2 
PLA 199 ± 44 221 ± 47 204 ± 52 220 ± 50 211 ± 5 Treatment 0.95 
(ml/min) PWS 198 ± 51 225 ± 55 213 ± 55 231 ± 61 216 ± 6 Time < 0.001 
PWS150 207 ± 50 238 ± 46 204 ± 45 216 ± 47 212 ± 6 T x T 0.08 
Overall 201 ± 48 228 ± 49* 207 ± 50 222 ± 53* 
RER PLA 0.83 ± 0.05 0.86 ± 0.06 0.84 ± 0.05 0.89 ± 0.06 0.86 ± 0.01 Treatment 0.57 
PWS 0.83 ± 0.05 0.89 ± 0.05 0.84 ± 0.06 0.87 ± 0.05 0.86 ± 0.01 Time < 0.001 
PWS150 0.82 ± 0.04 0.88 ± 0.05 0.82 ± 0.04 0.85 ± 0.04 0.85 ± 0.01 T x T 0.24 
Overall 0.83 ± 0.05 0.88 ± 0.05* 0.83 ± 0.05 0.87 ± 0.05*  
REE 
PLA 1,686 ± 423 1,848 ± 369 1,718 ± 371 1,769 ± 359 1,713 ± 46.4 Treatment 0.94 
(Kcal/day) 
PWS 1,683 ± 426 1,795 ± 401 1,605 ± 329 1,763 ± 406 1,726 ± 44.4 Time < 0.001 
PWS150 1,672 ± 389 1,783 ± 420 1,712 ± 432 1,755 ± 465 1,747 ± 48.1 T x T 0.61 
Overall 1,680 ± 405 1,808 ± 391* 1,678 ± 376 1,762 ± 405* 
Values are means ± standard deviations. REE values were analyzed by MANOVA with repeated measures. Greenhouse-Geisser 
treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-levels. MANOVA 
analysis revealed overall Wilks’ Lambda treatment (p = 0.97), time (p < 0.0001), and treatment x time (p = 0.76). * represents p < 
0.05 difference from pre-ingestion day 0. 
Table 4.8 presents the results for the Stroop Word-Color test. MANOVA analysis 
revealed overall Wilks’ Lambda treatment x time (p = 0.41). The cognitive function test 
results indicate a significant interaction among treatments for the Word test between 
PWS150 and PLA (p = 0.027). The results of our study indicate that there was a 
significant change from day 0 in cognitive function as determined by the Stroop Word-
Color Test (Fig. 4.6). In the regard, we observed significant changes in Word count, 
Color recognition, Word-Color assessment, and total Stroop results. There no other 
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Table 4.5 Cumulative Values for REE Measurement (AUC) 
Variable Treatment Day 0 Day 0 Day 7 Day 7 
 
  
  
Pre-Ingestion Post-Ingestion Pre-Ingestion Post-Ingestion  
  
  
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE 
 
p-level 
VO2 PLA 7,064 ± 1,827  7,448 ± 1,582 7,228 ± 1,509  7,338 ± 1,500 7,121 ± 187 Treatment 0.99 
(ml/30 
min) 
PWS 6,865 ± 1,547 7,398 ± 1,595 7,226 ± 1,825 7,578 ± 1,881 7,267 ± 195 Time 0.002 
 PWS150 7,135 ± 1,705 7,620 ± 1,891 7,081 ± 1,717 7,169 ± 1,724 7,251 ± 199 T x T 0.26 
 Overall 7,020 ± 1,664 7,490 ± 1,671* 7,176 ± 1,665 7,363 ± 1,693*    
VCO2 
PLA 5,823 ± 1,431  5,925 ± 1,324 6,530 ± 1,202 6,312 ± 1,303 6,002 ± 163 Treatment 0.96 
(ml/30 
min) 
PWS 5,694 ± 1,194 6,075 ± 1,434 6,584 ± 1,400 6,754 ± 1,709 6,277 ± 169 Time < 0.001 
 
PWS150 5,979 ± 1,554 5,988 ± 1,671 6,614 ± 1,638 6,270 ± 1,591 6,213 ± 183 T x T 0.26 
 Overall 5,832 ± 1,379 5,998 ± 1,463* 6,578 ± 1,406 6,450 ± 1,540*    
RER 
PLA 23.8 ± 1.60 23.9 ± 1.52 23.9 ± 1.52 25.0 ± 1.68 24.5 ± 0.21 Treatment 0.46 
 PWS 24.1 ± 1.18 24.4 ± 1.66 24.4 ± 1.66 25.9 ± 1.64 25.0 ± 0.19 Time < 0.001 
 
PWS150 24.1 ± 2.73 24.3 ± 1.64 24.3 ± 1.64 25.3 ± 1.54 24.7 ± 0.20 T x T 0.76 
 Overall 24.0 ± 1.50 24.2 ± 1.60* 24.2 ± 1.60 25.4 ± 1.63*    
REE PLA 48,831 ± 12,375 52,790 ± 9,952 49,785 ± 10,786 51,248 ± 10,383 49,452 ± 1,324  Treatment 0.99 
(Kcal/30 
min) 
PWS 48,827 ± 11,773 52,486 ± 11,462 49,550 ± 12,512  51,441 ± 11,582 50,576 ± 1,341 Time < 0.001 
 PWS150 48,270 ± 10,818 51,927 ± 11,873 49,853 ± 12,247 51,914 ± 13,839 50,491 ± 1,387 T x T 0.98 
 Overall 48,636 ± 11,431 52,387 ± 10,966 49,727 ± 11,690 51,545 ± 11,857    
Values are means ± standard deviations. Cumulative REE values (AUC) were analyzed by MANOVA with repeated measures. Greenhouse-Geisser 
treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-levels. MANOVA analysis revealed 
overall Wilks’ Lambda treatment (p = 0.95), time (p < 0.0001), and treatment x time (p = 0.78). * represents p < 0.05 difference from pre-ingestion day 0. 
 
 
 
significant interaction for Color count (p = 0.10, partial η2 = 0.06 – medium effect) and 
total Stroop results (p = 0.07, partial η2 = 0.07 – medium effect). The results from 
cognitive function test accepts the directional hypothesis 4 which states that PWS 
supplementation will improve markers of cognitive function.  
Exercise Performance  
Upper and Lower Body Strength 
Table 4.9 presents the results of bench press and leg press performance including 
lifting volume during the 3rd set and total lifting volume. Figures 4.7 and 4.8 present the 
changes from day 0 in bench and leg press 3rd set lifting volume and total lifting volume. 
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Participants performed three sets of bench press and leg press using a load equivalent 
to70% of their 1RM. The first two sets consisted of ten repetitions each. The third set 
consisted of maximal repetitions performed. MANOVA analysis for bench and leg press 
lifting volume revealed overall Wilks' Lambda treatment x time (p = 0.74). Univariate 
analysis did not show any significant interaction for bench and leg press performance. 
However, the percent change from day 0 in bench press lifting volume during the 3rd set 
was 13.7%, 4.6%, and 0.2% with PLA, PWS, and PWS150, respectively; bench press 
total lifting volume changed by 6.8%, -0.5%, and 12.8% for PLA, PWS, and PWS150, 
respectively; leg press lifting volume during the 3rd set was 15.4%, 13.4%, and 5.5% 
with PLA, PWS, and PWS150, respectively; and the leg press total lifting volume 
increased by 8.7%, 7.4%, and 4.8% with PLA, PWS, and PWS150, respectively. 
Table 4.10 presents the results for upper body power output including mean power, peak 
power, and mean velocity during the 3rd set. Figure 4.9 presents the changes from day 0 
in bench press mean power, peak power, and mean velocity. The upper body power 
output was measured by Tendo Fitrodyne. MANOVA analysis for upper body power 
output revealed overall Wilks' Lambda treatment x time (p = 0.96). Overall, there was no 
significant differences among treatments in upper body mean power, peak power, and 
mean velocity; however, the percent change from day 0 in peak power was 3.3%, -0.83, 
and 7.3% with PLA PWS, and PWS150, respectively; mean power increased by 1.5%, 
2.7%, and 6.3% with PLA, PWS, and PWS150, respectively; and mean velocity 
increased with by 4.7%, 1.8%, and 5.4% with PLA, PWS, and PWS150, respectively. 
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Table 4.6 Heart Rate and Blood Pressure Measurement Before and After Supplement Ingestion 
Day 0  Day 0  Day 0  Day 0  Day 0  Day 7  Day 7  Day 7  Day 7  Day 7  
Variable Treatment 
Pre-
ingestion 
Post-
ingestion 
Post-Bench 
press 
Post-Leg press Post-Wingate Pre-
ingestion 
Post-
ingestion 
Post-Bench 
press 
Post-Leg press Post-Wingate 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE p-level 
HR  
PLA 62.8 ± 7.8 62.4 ± 9.0 93.6 ± 18.1 109.4 ± 16.8 126.6 ± 30.3 61.5 ± 10.0 58.7 ± 10.2 94.7 ± 13.9 103.5 ± 27.3 120.5 ± 17.3 89.4 ± 2.2  Treatment 0.02 
(b/min) 
PWS 60.4 ± 10.6 61.8 ± 10.3 99.6 ± 18.8 105.3 ± 20.3 131.2 ± 13.6 57.9 ± 7.5 58.1 ± 7.1 102.6 ± 11.4 107.6 ± 32.8 131.7 ± 12.9 91.6 ± 2.3 Time < 0.001 
PWS150 59.3 ± 9.1 59.2 ± 7.9 110.2 ± 13.8 122.3 ± 22.1 137.2 ± 15.6 58.6 ± 9.7 62.2 ± 12.9 109.4 ± 15.2 108.7 ± 27.4 136.9 ± 12.1 96.4 ± 2.5 T x T 0.08 
Overall 60.8 ± 9.2 61.1 ± 9.0 101.1 ± 18.1* 112.3 ± 20.8* 131.7 ± 21.3* 59.3 ± 9.1 59.7 ± 10.3 102.2 ± 14.7* 106.6 ± 28.8* 129.7 ± 15.6* 
SBP 
PLA 115.6 ± 7.1 116.4 ± 8.2 130.2 ± 10.7 136.4 ± 17.4 143.8 ± 17.5 117.7 ± 9.5 116.4 ± 8.5 125.7 ± 14.3a,b 134.7 ± 16.4 144.0 ± 17.4 128.1 ± 1.2 Treatment 0.93 
(mmHg) 
PWS 114.1 ± 8.7 113.3 ± 6.9 128.3 ± 11.0a 135.4 ± 14.4 143.1 ± 17.2 113.7 ± 7.8 116.1 ± 8.0 138.9 ± 13.1c 145.1 ± 15.3 151.6 ± 17.2 130.0 ± 1.3 Time < 0.001 
PWS150 114.8 ± 5.9 115.7 ± 7.5 136.6 ± 9.9b 140.1 ± 15.8 149.3 ± 17.2 116.8 ± 7.3 114.9 ± 6.7 137.3 ± 13.2c 140.6 ± 15.6 149.6 ± 17.2 131.6 ± 1.3 T x T 0.02 
Overall 114.8 ± 7.2 115.1 ± 7.5 131.7 ± 11.1* 137.3 ± 15.7* 145.4 ± 17.2* 116.1 ± 8.3 115.8 ± 7.7 134.0 ± 14.5* 140.1 ± 16.1*  148.4 ± 17.3* 
DBP 
PLA 71.1 ± 7.3 69.0 ± 5.8 70.6 ± 7.5 69.0 ± 8.8 67.0 ± 10.0 71.3 ± 7.9 68.7 ± 7.9 67.2 ± 8.6 65.0 ± 9.7 67.9 ± 10.0 69.0 ± 0.62 Treatment 0.99 
(mmHg) 
PWS 69.5 ± 7.2  68.5 ± 6.6 70.7 ± 7.7 66.8 ± 8.4 66.0 ± 10.4 71.5 ± 7.2  67.0 ± 7.6 62.2 ± 8.6 62.9 ± 7.8 61.7 ± 9.3 66.7 ± 0.63 Time < 0.001 
PWS150 67.1 ± 5.3 66.5 ± 6.2 66.3 ± 9.8 63.1 ± 10.2 65.2 ± 8.7 68.2 ± 6.6 68.5 ± 5.7 65.4 ± 9.0 64.1 ± 9.7 62.7 ± 9.7 65.7 ± 0.61 T x T 0.49 
Overall 69.2 ± 6.7 68.0 ± 6.2 69.2 ± 8.5 64.0 ± 9.0* 67.0 ± 10.0 70.3 ± 7.3 68.1 ± 7.0 64.9 ± 8.8* 64.0 ± 9.0* 64.1 ± 9.9* 
Values are means ± standard deviations. Hemodynamic data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) 
interaction p-levels are reported with univariate treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.058), time (p < 0.0001), and treatment x time (p = 0.13).  a 
denotes a significant difference from PWS150. b denotes a significant difference from PWS. c denotes a significant difference from PWS. * represents p < 0.05 difference from pre-ingestion day 0. 
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Table 4.7 Readiness to Perform-Visual Analogue Scale 
Treatment Time (wks) 
 Day 0 Day 2 Day 4 Day 7 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE p-level 
Looking forward 
to today's workout 
PLA 3.89 ± 0.65 3.89 ± 0.73 3.47 ± 0.61 3.52 ± 0.90 3.70 ± 0.09 Treatment 0.79 
PWS 3.84 ± 0.76 3.68 ± 0.58 3.36 ± 0.83 3.68 ± 0.88 3.64 ± 0.09 Time 0.01 
PWS150 3.68 ± 0.74 3.52 ± 0.61 3.47 ± 0.84 3.63 ± 0.89 3.58 ± 0.09 T x T 0.65 
Overall 3.80 ± 0.71 3.70 ± 0.65 3.43 ± 0.75* § 3.61 ± 0.88 
Optimistic about 
my future 
performance 
PLA 3.89 ± 0.99 3.89 ± 1.04 3.84 ± 0.89 3.52 ± 0.84 3.70 ± 0.11 Treatment 0.97 
PWS 3.78 ± 0.78 3.73 ± 0.87 3.73 ± 0.73 3.68 ± 0.88 3.71 ± 0.10 Time 0.22 
PWS150 3.78 ± 0.78 3.73 ± 0.80 3.73 ± 0.93 3.68 ± 1.10 3.70 ± 0.11 T x T 0.79 
Overall 3.82 ± 0.84 3.78 ± 0.90 3.77 ± 0.84 3.63 ± 0.93 
Feel vigorous and 
energetic 
PLA 3.31 ± 1.00 3.47 ± 0.90 3.63 ± 0.89 3.05 ± 0.97 3.37 ± 0.11 Treatment 0.78 
PWS 3.26 ± 0.99 3.52 ± 0.96 3.15 ± 0.68 3.15 ± 0.83 3.28 ± 0.10 Time 0.08 
PWS150 3.31 ± 0.74 3.21 ± 0.78 3.31 ± 1.00 3.05 ± 0.84 3.22 ± 0.10 T x T 0.48 
Overall 3.29 ± 0.90 3.40 ± 0.88 3.36 ± 0.87 3.08 ± 0.87
§  
Appetite is great 
PLA 3.57 ± 1.01 3.78 ± 0.91 3.73 ± 0.73 3.68 ± 1.00 3.70 ± 0.10 Treatment 0.92 
PWS 3.84 ± 0.83 3.89 ± 0.87 3.63 ± 0.83 3.68 ± 1.00 3.76 ± 0.10 Time 0.09 
PWS150 3.84 ± 1.06 4.00  ± 1.00 3.78 ± 1.18 3.57 ± 1.01 3.80 ± 0.12 T x T 0.60 
Overall 3.75 ± 0.96 3.89 ± 0.91 3.71 ± 0.92 3.64 ± 0.99§ 
Have little muscle 
soreness 
PLA 3.31 ± 1.00 3.15 ± 0.89 3.31 ± 0.94 2.94 ± 1.22 3.18 ± 0.12 Treatment 0.89 
PWS 3.57 ± 0.96 2.89  ± 0.93 2.68 ± 1.20 3.15 ± 1.11 3.08 ± 0.13 Time 0.11 
PWS150 3.21 ± 1.22 3.05 ± 1.12 3.10 ± 1.32 2.94 ± 1.22 3.08 ± 0.14 T x T 0.28 
Overall 3.36 ± 1.06 3.03 ± 0.98 3.03 ± 1.17 3.01 ± 1.17* 
Values are means ± standard deviations. Readiness to perform data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser 
treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-levels. MANOVA analysis 
revealed overall Wilks’ Lambda treatment (p = 0.99), time (p = 0.08), and treatment x time (p = 0.36). * represents p < 0.05 difference from Day 0. 
§ represents p < 0.05 difference from Day 2. represents p < 0.05 difference from Day 4.
Table 4.8 Cognitive Function 
Treatment Time (wks) 
Day 0 Day 2 Day 4 Day 7 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE p-level 
Word  
(counts) 
PLA 114.7 ± 14.2 118.2 ± 16.0 118.1 ± 16.5  116.0 ± 14.9 a 116.7 ± 1.7 Treatment 0.68 
PWS 112.1 ± 19.0 119.8 ± 18.2 118.6 ± 18.9  118.6 ± 16.9  117.3 ± 2.0 Time < 0.001 
PWS150 115.4 ± 16.3 119.9 ± 18.6 121.7 ± 15.6  126.9 ± 20.9 c 121.0 ± 2.0 T x T 0.02 
Overall 114.1 ± 16.4 119.3 ± 17.4* 119.5 ± 16.8* 120.5 ± 18.0* 
Color  
(counts) 
PLA 84.4 ± 11.4 88.4 ± 13.2 87.3 ± 12.8 88.9  ± 11.6 87.3 ± 1.4 Treatment 0.60 
PWS 83.2 ± 11.9 86.2 ± 15.1 85.4 ± 12.4 85.5 ± 12.4 85.0 ± 1.4 Time < 0.001 
PWS150 85.7 ± 13.8 87.1 ± 15.6 89.7 ± 13.7 93.8 ± 15.2 89.1 ± 1.6 T x T 0.10 
Overall 84.4 ± 12.5 87.2 ± 14.5* 87.5 ± 12.9* 89.4 ± 13.4* 
Word-Color  
(counts) 
PLA 59.8 ± 12.6 63.1 ± 13.2 62.0 ± 14.0 63.3 ± 12.8 62.5 ± 1.5 Treatment 0.82 
PWS 60.0 ± 16.1 63.1 ± 16.0 61.9 ± 15.1 63.4 ± 12.2 62.1 ± 1.6 Time < 0.001 
PWS150 59.8 ± 12.6 64.1 ± 14.6 65.3 ± 14.1 68.3 ± 14.2 64.5 ± 1.6 T x T 0.70 
Overall 60.1 ± 13.7 63.4 ± 14.4* 63.1 ± 14.3* 65.6 ± 13.0*  
Total Stroop PLA 259.0 ± 33.9  269.8 ± 38.0 267.5 ± 39.7 270.3 ± 34.5 266.6 ± 4.15 Treatment 0.67 
Results PWS 255.3 ± 42.5 269.2 ± 44.2 266.0 ± 42.3 267.6 ± 39.3 264.5 ± 4.78 Time < 0.001 
(counts) PWS150 261.7 ± 40.8 271.2 ± 44.0 276.9 ± 39.6 289.1 ± 47.0 274.7 ± 4.97 T x T 0.07 
Overall 258.7 ± 38.6 270.0 ± 41.4* 270.1 ± 40.1* 275.7 ± 41.0*  
Values are means ± standard deviations. Cognitive function data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser treatment 
(T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-levels. MANOVA analysis revealed overall 
Wilks’ Lambda treatment (p = 0.87), time (p < 0.001), and treatment x time (p = 0.41). a denotes a significant difference from PWS150. b denotes a 
significant difference from PWS. c denotes a significant difference from PLA.* represents p < 0.05 difference from day 0. represents p < 0.05 
difference from Day 4.  
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 Table 4.9 Bench Press and Leg Press Endurance 
Variable Treatment Day 0 Day 7 
Mean ± SD Mean ± SD Mean ± SE p-level 
Bench Press 3rd Set  PLA 803 ± 310 806 ± 321 794 ± 53 Treatment 0.72 
Lifting Volume (kg) PWS 856 ± 318 888 ± 320 872 ± 51  Time 0.36 
PWS150 866 ± 371 892 ± 320 879 ± 55 T x T 0.86 
Overall 842 ± 329 862 ± 317 
Bench Press Total  PLA 2,166 ± 664 2,551 ± 1,768 2,358 ± 216 Treatment 0.88 
Lifting Volume (kg) PWS 2,241 ± 578 2,226 ± 565 2,234 ± 91 Time 0.27 
PWS150 2,251 ± 663 2,276 ± 630 2,264 ± 103 T x T 0.33 
Overall 2,219 ± 626 2,351 ± 1,120 
Leg Press 3rd Set  PLA 6,401 ± 2,173 7,472 ± 2,627 6,936 ± 395 Treatment 0.12 
Lifting Volume (kg) PWS 7,459 ± 1,932 8,146 ± 3,093 7,802 ± 416 Time 0.08 
PWS150 8,604 ± 3,403 8,510 ± 2,573 8,557 ± 482 T x T 0.31 
Overall 7,488 ± 2,695 8,043 ± 2,758 
Leg Press Total  PLA 13,090 ± 3,487 14,161 ± 3,445 13,625 ± 561 Treatment 0.31 
Lifting Volume (kg) PWS 14,210 ± 3,147 14,835 ± 4,110 14,523 ± 588 Time 0.75 
PWS150 16,276 ± 9,127 15,199 ± 3,665 15,737 ± 1,116 T x T 0.39 
Overall 14,525 ± 5,970 14,732 ± 3,708 
Values are means ± standard deviations. Bench press and leg press performance were analyzed by MANOVA with 
repeated measures. Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are 
reported with univariate treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.38), 
time (p = 0.10), and treatment x time (p = 0.64).   
Figure 4.6 Data Represent the Change from Day 0 to Day 7 in Stroop Testing Associated Treatment. 
Statistical Significance is Noted as: (a) Significant vs. Placebo (p = 0.008), (b) Significant vs. PWS (p 
< 0.03) and (c) Significant vs. PWS (p < 0.05). 
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Anaerobic Capacity Test 
Results of the Wingate testing are presented in Table 4.11. Figure 4.10 presents 
the changes from day 0 in Wingate mean power, peak power, total work, minimum 
power, and rate of fatigue. A MANOVA analysis was run in order to assess changes in 
anaerobic capacity variables. MANOVA analysis revealed overall Wilks' Lambda 
treatment x time (p = 0.44). Overall, no significant interactions were found for Wingate 
mean power (p = 0.23); peak power (p = 0.87); total work (p = 0.16); minimum power (p 
= 0.09, partial η2 = 0.07 – medium effect); and rate of fatigue (p = 0.55). However, we 
Figure 4.7 Changes from Day 0 (95% CI) in Bench Press 3rd Set Lifting Volume and Total Lifting Volume. 
Figure 4.8 Changes from Day 0 (95% CI) in Leg Press 3rd Set Lifting Volume and Total Lifting Volume. 
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observed a significant change in Wingate mean power at day 7 only in PWS150 (26.0 
95% CI 1.85, 50.3) but not PWS (-3.83 95% CI -28.7, 21.0), and PLA (8.88 95% 
Table 4.10 The 3rd Set of Bench Press Tendo Performance 
Variable Treatment Day 0 Day 7 
Mean ± SD Mean ± SD Mean ± SE p-level 
Tendo Mean Power PLA 251 ± 83 265 ± 89 259 ± 13 Treatment 0.91 
(Watt) PWS 247 ± 67 254 ± 73 247 ± 11 Time 0.08 
PWS150 258 ± 80 264 ± 70 261 ± 12 T x T 0.80 
Overall 252 ± 76 261 ± 76 
Tendo Peak Power PLA 331 ± 116 344 ± 121 334 ± 19  Treatment 0.97 
(Watt) PWS 341 ± 110 346 ± 115 339 ± 18 Time 0.24 
PWS150 333 ± 111 340 ± 101 337 ± 17 T x T 0.88 
Overall 335 ± 110 343 ± 110 
Tendo Mean Velocity PLA 0.37 ± 0.06 0.39 ± 0.07 0.38 ± 0.01 Treatment 0.56 
(meter/s) PWS 0.36 ± 0.05 0.37 0.06 0.37 ± 0.01 Time 0.053 
PWS150 0.37 ± 0.06 0.39 ± 0.04 0.39 ± 0.01 T x T 0.81 
Overall 0.37 ± 0.06 0.38 ± 0.06 
Values are means ± standard deviations. Bench press Tendo unit variables were analyzed by MANOVA with repeated measures. 
Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-
levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.83), time (p = 0.27), and treatment x time (p = 0.96). 
CI -17.5, 35.2). After 7 days of supplementation, percent change in peak power was -
1.6%, 1.1%, and -1.2% for PLA, PWS, and PWS150, respectively; mean power changed 
by 4.5%, 0.8%, and 1.2% for PLA, PWS, and PWS150, respectively; total work 
increased by 2.0%, 0.9%, and 3.7% for PLA, PWS, and PWS150, respectively; 
minimum power changed by -6.3%, 11.7%, and 11.2% for PLA, PWS, and PWS150, 
respectively; and mean power changed by -0.3%, -1.0%, and -0.7% for PLA, PWS, and 
PWS150, respectively. The results from exercise performance tests analyses provide 
evidence which accepts the directional hypothesis 5 which states that PWS 
supplementation will affect exercise performance. 
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Clinical Chemistry Panels 
Table 4.12 presents whole blood markers assessment. MANOVA analysis 
revealed overall Wilks' Lambda treatment x time (p = 0.09). Univariate analysis revealed 
no significant treatment by time interaction for any whole blood marker. After 7 days of 
supplementation, percent change in MCV was -0.02%, 0.37%, and -0.16% for PLA, 
Figure 4.9 Changes from Day 0 (95% CI) in Bench Press Mean Power, Peak Power, and Mean Velocity. 
75 
Table 4.11 Anaerobic Sprint Capacity 
Variable Treatment Day 0 Day 7 
Mean ± SD Mean ± SD Mean ± SE p-level 
Mean Power PLA 551 ± 114 560 ± 110 550 ± 18 Treatment 0.83 
(Watt) PWS 566 ± 125 562 ± 109 558 ± 18 Time 0.15 
PWS150 567 ± 118 593 ± 159 580 ± 22 T x T 0.23 
Overall 562 ± 109 573 ± 128 
Peak Power PLA 1,523 ± 382 1,466 ± 451 1,547 ± 70 Treatment 0.65 
(Watt/kg) PWS 1,610 ± 492 1,595 ± 491 1,614 ± 77 Time 0.27 
PWS150 1,646 ± 411 1,611 ± 535 1,628 ± 76 T x T 0.87 
Overall 1,597 ± 427 1,561 ± 490 
Total Work PLA 16,687 ± 3,467 16,644 ± 3,290 16,531 ± 548 Treatment 0.87 
(Joules) PWS 16,515 ± 3,536 17,096 ± 3,329 16,612 ± 553 Time 0.50 
PWS150 17,329 ± 3,650 16,644 ± 3290 17,237 ± 575 T x T 0.16 
Overall 16,859 ± 3,507 16,977 ± 3,335 
Minimum Power PLA 237 ± 79 221 ± 77 217 ± 14 Treatment 0.53 
(Watt) PWS 219 ± 78 239 ± 70 227 ± 12 Time 0.22 
PWS150 235 ± 88 189 ± 117 212 ± 17 T x T 0.09 
Overall 230 ± 81 216 ± 92 
Rate of Fatigue PLA 85.9 ± 7.9 85.4 ± 8.0 87.6 ± 1.3 Treatment 0.69 
(%) PWS 86.4 ± 8.5 83.3 ± 5.5 85.8 ± 1.3 Time 0.50 
PWS150 86.5 ± 10.1 87.1 ± 11.4 86.8 ± 1.7 T x T 0.55 
Overall 86.3 ± 8.8 85.3 ± 8.7 
Values are means ± standard deviations. Anaerobic sprint capacity data were analyzed by MANOVA with repeated measures. 
Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate 
treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.89), time (p = 0.29), and treatment x 
time (p = 0.44). 
PWS, and PWS150, respectively; MCH changed by 4.6%, 5.4%, and -0.31% for PLA, 
PWS, and PWS150, respectively; MCHC changed by 4.8%, 5.1%, and -0.01% for PLA, 
PWS, and PWS150, respectively; RBCDW changed by 2.5%, 1.4%, and -1.4% for PLA, 
PWS, and PWS150, respectively; platelet count changed by -8.0%, -7.1%, and 1.1% for 
PLA, PWS, and PWS150, respectively; WBC changed by -1.6%, 3.7%, and -0.95% for 
PLA, PWS, and PWS150, respectively; RBC changed by -4.2%, -5.7%, and 2.9% for 
PLA, PWS, and PWS150, respectively; hematocrit changed by -5.8%, -3.6%, and 2.1% 
for PLA, PWS, and PWS150, respectively; and hemoglobin changed by -1.5%, -1.2%, 
and 1.6% for PLA, PWS, and PWS150, respectively. 
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Blood Chemistry 
General markers of health are presented in Table 4.13. MANOVA analysis 
revealed overall Wilks’ Lambda treatment x time (p = 0.64). Although a significant time 
effect was detected for serum Cr (p = 0.02), univariate analysis did not show any 
significant treatment x time interaction or mean changes for any health marker. After 7 
days of supplementation, percent change in ALP was -5.0%, 2.1%, and -0.95% for PLA, 
PWS, and PWS150, respectively; ALT changed by 13.9%, -1.4%, and -1.3% for PLA, 
PWS, and PWS150, respectively; AST changed by 0.97%, 1.6%, and 9.5% for PLA,  
Figure 4.10 Changes from Day 0 (95% CI) in Wingate Mean Power, Peak Power, Minimum Power, Total 
Work, and Rate of Fatigue. * Represents p < 0.05 difference from day 0. 
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PWS, and PWS150, respectively; CK changed by 14.9%, 1.7%, and 11.1% for PLA, 
PWS, and PWS150, respectively; LDH changed by 4.7%, 1.3%, and 0.61% for PLA, 
PWS, and PWS150, respectively; BUN changed by -3.4%, 2.4%, and 1.6% for PLA, 
PWS, and PWS150, respectively; creatinine ratio changed by 0.51%, -0.52%, and 1.5% 
for PLA, PWS, and PWS150, respectively; BUN:creatinine ratio changed by -3.1%, 
3.5%, and 0.92% for PLA, PWS, and PWS150, respectively; and Cr changed by 14.3%,
 13.7%, and 13.9% for PLA, PWS, and PWS150, respectively. Findings for plasma lipid 
and glucose levels are presented in Table 4.14. MANOVA analysis revealed overall 
Wilks’ Lambda treatment x time (p = 0.34). Although a tendency was observed towards 
a significant interaction for TC/HDL ratio between PLA and PWS (p = 0.09, partial η2 = 
0.08 – medium effect), univariate analysis revealed no significant time x treatment 
interaction for any plasma lipids and glucose. After 7 days of supplementation, percent 
change in TC was -5.2%, 2.4%, and -0.51% for PLA, PWS, and PWS150, respectively; 
HDL changed by 0.21%, 0.89%, and 4.6% for PLA, PWS, and PWS150, respectively; 
TC:HDL ratio changed by -4.4%, 2.8%, and 1.1% for PLA, PWS, and PWS150, 
respectively; LDL changed by 0.71%, 9.2%, and -0.28% for PLA, PWS, and PWS150, 
respectively; TG changed by -5.2%, 10.9%, and -4.7% for PLA, PWS, and PWS150, 
respectively; and glucose changed by -6.1%, 5.5%, and 0.86% for PLA, PWS, and 
PWS150, respectively. Table 4.15 indicates Chi squared categorical analysis. We did not 
observe any significant effects when examining changes for blood parameters outside of 
normal clinical boundaries. This is not to say that some participant’s blood parameters 
did not exceed normal clinical limits at follow-up. However, an examination of our data 
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Table 4.12 Whole Blood Markers 
Marker Treatment Day 0 Day 7    
  Mean ± SD Mean ± SD Mean ± SE  p-level 
MCV PLA 93.2 ± 3.7 88.8 ± 21.6 91.0 ± 2.5 Treatment 0.57 
(fL) PWS 93.0 ± 3.4 93.4 ± 3.7 93.2 ± 0.5 Time 0.34 
 PWS150 93.4 ± 3.5 93.2 ± 3.5 93.3 ± 0.5 T x T 0.35 
 Overall 93.2 ± 3.5 91.8 ± 12.8    
MCH PLA 31.0 ± 1.8 31.0 ± 8.4 31.0 ± 0.9 Treatment 0.54 
(pg/cell) PWS 31.1 ± 2.5 32.8 ± 3.5 31.9 ± 0.5 Time 0.49 
 PWS150 32.2 ± 2.9 32.0 ± 2.4 32.1 ± 0.4 T x T 0.48 
 Overall 31.4 ± 2.4 31.9 ± 5.4    
MCHC PLA 33.3 ± 1.1 33.0 ± 9.0 33.1 ± 1.0 Treatment 0.43 
(g/dl) PWS 33.4 ± 1.8 35.1 ± 3.8 34.3 ± 0.5 Time 0.58 
 PWS150 34.4 ± 2.8 34.3 ± 2.4 34.4 ± 0.4 T x T 0.53 
 Overall 33.7 ± 2.0 34.1 ± 5.7    
RBCDW PLA 12.8 ± 0.5 12.4 ± 3.0 12.6 ± 0.3 Treatment 0.47 
(%) PWS 12.9 ± 0.6 13.0 ± 0.7 13.0 ± 0.1 Time 0.60 
 PWS150 13.0 ± 0.6 12.8 ± 0.7 12.9 ± 0.1 T x T 0.64 
 Overall 12.9 ± 0.6 12.8 ± 1.8    
Platelet Count PLA 239 ± 51 198 ± 85 218 ± 11 Treatment 0.98 
(x103/μl) PWS 232 ± 59 211 ± 65 221 ± 10 Time 0.01 
 PWS150 221 ± 51 220 ± 49 221 ± 8 T x T 0.17 
 Overall 231 ± 53 210 ± 68*    
WBC PLA 6.5 ± 1.8 6.3 ± 1.7 6.4 ± 0.2 Treatment 0.77 
(x103/μl)  PWS 5.9 ± 1.5 6.1 ± 1.5 6.0 ± 0.2 Time 0.60 
 PWS150 6.3 ± 1.8 6.1 ± 1.7 6.2 ± 0.2 T x T 0.57 
 Overall 6.5 ± 1.8 6.1 ± 1.6    
RBC PLA 4.8 ± 0.4 4.3 ± 1.2 4.6 ± 0.1 Treatment 0.71 
(x106/μl ) PWS 4.8 ± 0.4 4.5 ± 0.5 4.6 ± 0.1 Time 0.053 
 PWS150 4.6 ± 0.4 4.7 ± 0.4 4.7 ± 0.1 T x T 0.10 
 Overall 4.8 ± 0.4 4.5 ± 0.8    
Hematocrit PLA 45.4 ± 4.1 39.9 ± 12.9 42.7 ± 1.6 Treatment 0.56 
(%) PWS 44.2 ± 4.4 42.5 ± 5.9 43.3 ± 0.8 Time 0.07 
 PWS150 44.1 ± 3.8 44.7 ± 4.2 44.4 ± 0.6 T x T 0.12 
 Overall 44.6 ± 4.1 42.4 ± 8.6    
Hemoglobin PLA 15.1 ± 1.4 14.0 ± 3.6 14.6 ± 0.4 Treatment 0.53 
(g/dl) PWS 15.0 ± 1.1 14.7 ± 1.2 14.9 ± 0.1 Time 0.23 
 PWS150 15.0 ± 1.1 15.2 ± 1.4 15.1 ± 0.2 T x T 0.18 
 Overall 15.0 ± 1.2 14.7 ± 2.3    
Values are means ± standard deviations. Whole blood markers were analyzed by MANOVA with repeated 
measures. Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are 
reported with univariate treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 
1.0), time (p = 0.43), and treatment x time (p = 0.09). * Represents p < 0.05 difference from day 0.  
 
 
 
shows these perturbations to be distributed equally across all treatments, inclusive of the 
PLA. The results from general health markers analyses provide evidence which accepts 
the directional hypothesis 6 which states that there will be no significant differences in 
health markers.  
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Short Sleep and Caffeine Questionnaires  
Tables 4.16, 4.17, and 4.18 present stimulant effects before and after 7 days of 
supplement ingestion. MANOVA analysis of SQQ revealed overall Wilks’ Lambda 
treatment x time (p = 0.26). MANOVA analysis did not indicate any significant 
interactions among treatments regarding sleep quality results. The results from SQQ 
provide evidence which accepts the directional hypothesis 7 which states that there will 
be no significant differences in sleep quality inventory.  
MANOVA analysis of CQ revealed overall Wilks’ Lambda treatment x time (p = 
0.33). The results from CQ indicated that there was a significant decrease in response to 
“Heavy feelings in arms and legs” in PWS150 compared to PWS and PLA treatments (p 
= 0.02). The overall multivariate test did not show any significant difference among 
treatments. Therefore, results from CQ provide evidence which accepts the directional 
hypothesis 8 which states that there will be no significant differences in caffeine 
tolerance inventory.
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Table 4.13 General Health Markers 
 Marker Treatment Day 0 Day 7    
   Mean ± SD Mean ± SD Mean ± SE  p-level 
L
iv
er
 E
n
zy
m
es
 
ALP PLA 85.6 ± 18.6 80.5 ± 19.3 83.0 ± 3.0 Treatment 0.61 
(U/L) PWS 88.5 ± 21.3 89.2 ± 22.5 88.9 ± 3.5 Time 0.25 
 PWS150 89.0 ± 22.0 86.5 ± 18.7 87.7 ± 3.5 T x T 0.45 
 Overall 87.6 ± 20.2 85.4 ± 20.3    
ALT PLA 28.4 ± 11.5 32.6 ± 21.5 30.5 ± 2.7 Treatment 0.89 
(U/L) PWS 29.1 ± 11.8 28.1 ± 10.9 28.6 ± 1.8 Time 0.81 
 PWS150 30.9 ± 13.6 28.9 ± 10.6 29.9 ± 2.1 T x T 0.29 
 Overall 29.4 ± 12.1 29.9 ± 15.3    
AST PLA 30.0 ± 9.5 30.0 ± 12.7 30.0 ± 1.8 Treatment 0.85 
(U/L) PWS 29.8 ± 9.3 28.8 ± 9.0 29.3 ± 1.4 Time 0.64 
 PWS150 26.8 ± 7.6 29.7 ± 11.8 28.3 ± 1.7 T x T 0.46 
 Overall 29.0 ± 8.9 29.5 ± 11.1    
M
u
sc
le
 E
n
zy
m
es
 
CK PLA 327 ± 267 328 ± 227 327 ± 41 Treatment 0.74 
(U/L) PWS 298 ± 237 260 ± 176 279 ± 33 Time 0.60 
 PWS150 251 ± 148 322 ± 205 286 ± 31 T x T 0.12 
 Overall 293 ± 223 301 ± 201    
LDH PLA 178 ± 36 184 ± 56 181 ± 7 Treatment 0.76 
(U/L) PWS 174 ± 29 175 ± 27 175 ± 4 Time 0.74 
 PWS150 175 ± 35 173 ± 32 174 ± 5 T x T 0.83 
 Overall 176 ± 33 178 ± 40    
K
id
n
ey
 E
n
zy
m
es
 &
 R
at
io
 
BUN PLA 18.5 ± 5.7 17.0 ± 3.5 17.8 ± 0.7 Treatment 0.90 
(mg/dl) PWS 17.2 ± 4.5 17.1 ± 4.5 17.2 ± 0.7 Time 0.31 
 PWS150 17.7 ± 5.4 17.5 ± 4.8 17.6 ± 0.9 T x T 0.59 
 Overall 17.8 ± 5.1 17.2 ± 4.2    
Creatinine PLA 1.34 ± 0.32 1.32 ± 0.28 1.33 ± 0.05 Treatment 0.83 
(mg/dl) PWS 1.34 ± 0.24 1.32 ± 0.22 1.33 ± 0.04 Time 0.76 
 PWS150 1.28 ± 0.19 1.29 ± 0.25 1.29 ± 0.04 T x T 0.90 
 Overall 1.32 ± 0.25 1.31 ± 0.25*    
BUN:Creatinine PLA 14.1 ± 4.3 13.3 ± 3.7 13.7 ± 0.6 Treatment 0.87 
Ratio PWS 13.2 ± 4.1 13.3 ± 4.3 13.2 ± 0.6 Time 0.39 
 PWS150 14.0 ± 4.5 13.7 ± 3.6 13.8 ± 0.7 T x T 0.65 
 Overall 13.8 ± 4.2 13.4 ± 3.9    
 
Creatine PLA 191.7 ± 69.9 205.7 ± 82.1 198.7 ± 12.2 Treatment 0.70 
(μM) PWS 191.6 ± 80.3 218.1 ± 98.4 204.8 ± 14.5 Time 0.02 
 PWS150 211.1 ± 86.8 235.1 ± 158.4 223.1 ± 20.5 T x T 0.85 
 Overall 198.2 ± 78.4 219.6 ± 116.2*    
Values are means ± standard deviations. Health markers were analyzed by MANOVA with repeated measures. Greenhouse-
Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-
levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.97), time (p = 0.91), and treatment x time (p = 
0.64). * Represents p < 0.05 difference from day 0.  
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Table 4.14 Blood Lipids and Glucose 
Marker Treatment Day 0 Day 7    
  Mean ± SD Mean ± SD Mean ± SE  p-level 
TC PLA 187.2 ± 46.2 172.3 ± 38.8 179.8 ± 6.9 Treatment 0.81 
(mg/dl) PWS 185.3 ± 32.6 188.2 ± 39.3 186.8 ± 5.7 Time 0.26 
 PWS150 186.6 ± 39.0 182.9 ± 36.6 184.8 ± 6.1 T x T 0.28 
 Overall 186.4 ± 38.9 181.2 ± 38.2    
HDL PLA 68.7 ± 21.9  67.3 ± 20.1 68.0 ± 3.3 Treatment 0.99 
(mg/dl) PWS 67.5 ± 17.3 67.7 ± 17.4 67.6 ± 2.7 Time 0.87 
 PWS150 67.4 ± 18.5 69.4 ± 19.4 68.4 ± 3.0 T x T 0.68 
 Overall 67.9 ± 19.0 68.1 ± 18.7    
TC:HDL PLA 2.77 ± 0.48 2.64 ± 0.48 2.71 ± 0.08 Treatment 0.72 
Ratio PWS 2.80 ± 0.52 2.86 ± 0.49 2.84 ± 0.08 Time 0.64 
 PWS150 2.77 ± 0.46 2.78 ± 0.50 2.78 ± 0.08 T x T 0.09 
 Overall 2.78 ± 0.48 2.76 ± 0.49    
LDL PLA 130.5 ± 53.1 127.6 ± 58.8 129.0 ± 8.9 Treatment 0.42 
(mg/dl) PWS 135.6 ± 55.2 146.7 ± 63.5 141.1 ± 9.5 Time 0.52 
 PWS150 153.5 ± 60.0 154.0 ± 68.5 153.8 ± 10.3 T x T 0.43 
 Overall 139.8 ± 59.1 142.8 ± 63.6    
TG PLA 96.1 ± 32.5 89.5 ± 35.9 92.8 ± 5.5 Treatment 0.39 
(mg/dl) PWS 102.7 ± 40.6 106.9 ± 45.0 104.8 ± 6.8 Time 0.22 
 PWS150 118.7 ± 63.9 96.4 ± 35.7 107.6 ± 8.4 T x T 0.28 
 Overall 105.8 ± 47.7 97.6 ± 39.1    
Glucose PLA 111.2 ± 26.7 101.1 ± 14.9 106.2 ± 3.5 Treatment 0.81 
(mg/dl) PWS 108.1 ± 22.8 112.1 ± 18.9 110.1 ± 3.3 Time 0.46 
 PWS150 108.7 ± 21.4 108.7 ± 23.6 108.7 ± 3.6 T x T 0.11 
 Overall 109.4 ± 23.3 107.3 ± 19.6    
Values are means ± standard deviations. Health markers were analyzed by MANOVA with repeated measures. 
Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with 
univariate treatment p-levels. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.99), time (p = 
0.41), and treatment x time (p = 0.32). 
 
 82 
 
 
Table 4.15 Prevalence of Blood Chemistry Changes Exceeding Normal Clinical Bounds 
  Marker Category PLA PWS PWS150 p-level 
L
ip
id
s 
&
 G
lu
co
se
 
Cholesterol No Change 10 11 9 0.87 
 Normal at Day 0, High at Day 7 2 3 2  
 High at Day 0, High at Day 7 2 3 4  
  High at Day 0, Normal at Day 7 5 2 4   
HDL-C No Change 19 19 18 0.36 
 Normal at Day 0, High at Day 7 0 0 0  
 High at Day 0, High at Day 7 0 0 0  
  High at Day 0, Normal at Day 7 0 0 1  
LDL-C No Change 9 9 8 0.41 
 Normal at Day 0, High at Day 7 1 3 0  
 High at Day 0, High at Day 7 5 6 8  
  High at Day 0, Normal at Day 7 4 1 3  
Triglycerides No Change 18 14 14 0.21 
 Normal at Day 0, High at Day 7 0 3 2  
 High at Day 0, High at Day 7 1 0 0  
  High at Day 0, Normal at Day 7 0 2 3  
Glucose No Change 9 8 10 0.19 
 Normal at Day 0, High at Day 7 2 5 2  
 High at Day 0, High at Day 7 6 5 3  
  High at Day 0, Normal at Day 7 5 0 2  
M
u
sc
le
 
LDH No Change 0 0 3 0.10 
 Normal at Day 0, High at Day 7 18 19 15  
 High at Day 0, High at Day 7 1 0 0  
  High at Day 0, Normal at Day 7 0 0 1  
Creatine No Change 0 0 3 0.41 
Kinase Normal at Day 0, High at Day 7 4 7 6  
 High at Day 0, High at Day 7 2 1 1  
  High at Day 0, Normal at Day 7 11 9 8  
K
id
n
ey
 
Creatinine No Change 0 0 3 0.18 
 Normal at Day 0, High at Day 7 9 10 11  
 High at Day 0, High at Day 7 3 1 0  
  High at Day 0, Normal at Day 7 4 3 3  
BUN No Change 0 0 3 0.13 
 Normal at Day 0, High at Day 7 17 18 13  
 High at Day 0, High at Day 7 0 1 1  
  High at Day 0, Normal at Day 7 2 0 2  
L
iv
er
 
ALP No Change 0 0 3 0.23 
 Normal at Day 0, High at Day 7 18 17 14  
 High at Day 0, High at Day 7 0 1 1  
  High at Day 0, Normal at Day 7 0 0 1  
ALT No Change 0 0 3 0.052 
 Normal at Day 0, High at Day 7 17 19 15  
 High at Day 0, High at Day 7 2 0 0  
  High at Day 0, Normal at Day 7 0 0 1  
AST No Change 0 0 3 0.12 
 Normal at Day 0, High at Day 7 18 18 14  
 High at Day 0, High at Day 7 1 1 2  
 High at Day 0, Normal at Day 7 0 0 0  
Data are frequency of occurrence. Significance is by chi-square analysis. 
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Table 4.16 Sleep Effects Before and After 7 Days of Supplement Ingestion (1) 
 Treatment Time (wks)    
   Day 0 Day 2 Day 4 Day 7    
   Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE  p-level 
Hours of 
Sleep 
during past 
48hrs (hrs) 
PLA  6.71 ± 1.15 7.26 ± 1.36 7.26 ± 1.32 6.86 ± 1.49 7.03 ± 0.15 Treatment 0.99 
PWS  7.04 ± 1.77 7.01 ± 1.39 7.02 ± 1.47 6.88 ± 1.17 7.07 ± 0.17 Time 0.81 
PWS150  6.83 ± 1.73 7.20 ± 1.51 6.93 ± 1.64 7.04 ± 2.02 7.06 ± 0.20 T x T 0.72 
Overall  7.04 ± 1.59 7.16 ± 1.40 7.07 ± 1.46 6.93 ± 1.57     
Time to 
Fall Asleep 
(min) 
PLA  17.2 ± 12.6 16.8 ± 16.0 14.8 ± 8.6 22.1 ± 21.2 17.7 ± 1.7 Treatment 0.45 
PWS  20.7 ± 15.9 23.0 ± 17.1 21.4 ± 16.9 24.4 ± 22.1 22.4 ± 2.0 Time 0.06 
PWS150  17.2 ± 12.6 20.0 ± 15.7 15.0 ± 7.6 19.1 ± 13.0 17.8 ± 1.3 T x T 0.78 
Overall  18.4 ± 12.9 19.9 ± 16.2 17.1 ± 12.0 21.8 ± 19.0    
Hours of 
Sleep 
PLA  6.71 ± 1.35 7.53 ± 3.08 7.34 ± 2.24 6.73 ± 2.95 7.08 ± 0.28 Treatment 0.78 
PWS  6.70 ± 1.69 7.10 ± 2.24 6.66 ± 2.11 7.13 ± 3.10 6.90 ± 0.27 Time 0.32 
PWS150  7.71 ± 3.48 7.30 ± 2.65 7.89 ± 3.64 6.78 ± 2.26 7.42 ± 0.35 T x T 0.16 
Overall  7.04 ± 2.37 7.31 ± 2.64 7.30 ± 2.75 6.88 ± 2.75    
Sleep 
Quality 
PLA (1) Very Good 1.94 ± 0.70 1.78 ± 0.53 1.84 ± 0.68 2.05 ± 0.70 1.91 ± 0.08 Treatment 0.35 
PWS (2) Fairly Good 2.00 ± 0.66 2.05 ± 0.84 2.15 ± 0.76 2.31 ± 0.82 2.13 ± 0.09 Time 0.04 
PWS150 (3) Fairly Bad 1.78 ± 0.53 2.05 ± 0.62 1.73 ± 0.65 2.00 ± 0.57 1.89 ± 0.07 T x T 0.26 
Overall (4) Very Bad 1.91 ± 0.63 1.96 ± 0.68 1.91 ± 0.71 2.12 ± 0.70*     
Enthusiasm 
PLA (1) No Problem 1.73 ± 0.80 1.73 ± 0.65 1.52 ± 0.51 1.73 ± 0.56 1.68 ± 0.07 Treatment 0.57 
PWS (2) Slight Problem 1.63 ± 0.68 1.52 ± 0.51 1.52 ± 0.61 1.52 ± 0.69 1.55 ± 0.07 Time 0.27 
PWS150 
(3) Somewhat of a 
problem 
1.84 ± 0.76 1.57 ± 0.60 1.68 ± 0.74 1.78 ± 0.71 1.72 ± 0.08 T x T 0.74 
Overall (4) Big Problem 1.73 ± 0.74 1.61 ± 0.59 1.57 ± 0.62 1.68 ± 0.65    
Bed Partner 
PLA (1) No Roommate 1.89 ± 1.28 1.94 ± 1.22 2.05 ± 1.31 2.15 ± 1.38 2.01 ± 0.15 Treatment 0.92 
PWS 
(2) Roommate in 
other Room 
2.10 ± 1.19 2.00 ± 1.20 1.94 ± 1.12 1.84 ± 1.11 1.97 ± 0.13 Time 0.79 
PWS150 
(3) Partner in 
Same room 
1.73 ± 1.14 1.89 ± 1.24 1.94 ± 1.22 1.89 ± 1.24 1.87 ± 0.14 T x T 0.19 
Overall (4) Partner in Bed 1.91 ± 1.19 1.94 ± 1.20 1.98 ± 1.20 1.96 ± 1.23    
Snoring 
PLA (1) Loud snoring 0.47 ± 1.12 0.31 ± 0.94 0.31 ± 0.94 0.15 ± 0.68 0.32 ± 0.11 Treatment 0.71 
PWS 
(2) Long pauses 
between breaths 
0.68 ± 1.24 0.15 ± 0.68 0.36 ± 0.95 0.47 ± 1.12 0.46 ± 0.12 Time 0.07 
PWS150 
(3) Twitching/ 
Jerking 
0.31 ± 0.94 0.31 ± 0.94 0.15 ± 0.68 0.31 ± 0.94 0.24 ± 0.09 T x T 0.55 
Overall (4) Disorientation 0.49 ± 1.10 0.26 ± 0.85* 0.28 ± 0.86* 0.31 ± 0.92    
Values are means ± standard deviations. Sleep quality data were analyzed by MANOVA with repeated measures. Greenhouse-Geisser 
treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment p-levels. MANOVA 
analysis revealed overall Wilks’ Lambda treatment (p = 0.86), time (p = 0.11), and treatment x time (p = 0.56).Time is expressed 
according to the 24 clock ± SD as hr:min. * represents p < 0.05 difference from Day 0. represents p < 0.05 difference from Day 4.   
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Table 4.17 Sleep Effects Before and After 7 Days of Supplement Ingestion (2) 
Sleep 
Characteristi
cs 
 Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
8 
Day 
9 
Day 
10 
Day 
11 
Day 
12 
Cochran’s 
Q 
Cannot get to 
sleep within 
30 minutes 
No 17 16 17 15 18 14 16 16 15 15 18 17 
0.46 
Yes 2 3 2 4 1 5 3 3 4 4 1 2 
Wake up in 
the middle of 
the night or 
early 
morning 
No 10 10 11 11 10 9 13 9 11 10 10 9 
0.68 
Yes 9 9 8 8 9 10 6 10 8 9 9 10 
Have to get 
up to use the 
bathroom 
No 14 13 15 15 12 14 14 14 14 15 15 15 
0.57 
Yes 5 6 4 4 7 5 5 5 5 4 4 4 
Cannot 
breathe 
comfortably 
No 18 19 18 19 19 19 19 19 19 19 19 19 
0.53 
Yes 1 0 1 0 0 0 0 0 0 0 0 0 
Cough or 
snore loudly 
No 17 17 18 18 18 18 18 18 18 19 19 19 
0.82 
Yes 2 2 1 1 1 1 1 1 1 0 0 0 
Feel too cold 
No 19 19 19 19 18 19 19 19 17 18 19 18 
0.34 
Yes 0 0 0 0 1 0 0 0 2 1 0 1 
Feel too hot 
No 17 17 16 15 19 18 18 18 18 18 18 18 
0.46 
Yes 2 2 3 4 0 1 1 1 1 1 1 1 
Had bad 
dreams 
No 19 19 19 19 19 19 19 18 19 18 18 18 
0.44 
Yes 0 0 0 0 0 0 0 1 0 1 1 1 
Have pain 
No 17 16 17 15 16 17 18 18 17 18 18 19 
0.56 
Yes 2 3 2 4 3 2 1 1 2 1 1 0 
The presented values are frequencies. Sleep quality nominal data were analyzed by non-parametric 
Cochran’s Q test.   
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Table 4.18 Stimulant Effects Before and After 7 Days of Supplement Ingestion (Caffeine) 
0 = Not at all, 1 = A little, 2 = Moderately, 3 = Quite a bit 4 = Extremely 
 Treatment Time (wks)    
  Day 0 Day 2 Day 4 Day 7    
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE  p-level 
Drowsy 
/sleepy 
PLA 1.31 ± 1.10 0.73 ± 0.80 0.73 ± 0.87 1.10 ± 1.14 0.97 ± 0.12 Treatment 0.87 
PWS 1.15 ± 1.11 0.84 ± 1.01 0.78 ± 0.71 0.94 ± 0.91 0.93 ± 0.11 Time 0.09 
PWS150 0.84 ± 0.95 0.84 ± 1.01 0.78 ± 0.91 0.94 ± 1.07 0.86 ± 0.11 T x T 0.74 
Overall 1.10 ± 1.06 0.80 ± 0.97 0.77 ± 0.82* 1.00 ± 1.03    
Self-confidence 
PLA 2.73 ± 0.87 2.42 ± 0.83 2.42 ± 0.76 2.42 ± 0.96 2.50 ± 0.10 Treatment 0.96 
PWS 2.63 ± 0.76 2.57 ± 0.90 2.57 ± 0.83 2.31 ± 1.00 2.51 ± 0.10 Time 0.03 
PWS150 2.42 ± 0.83 2.52 ± 0.96 2.52 ± 0.90 2.37 ± 1.02 2.45 ± 0.10 T x T 0.37 
Overall 2.59 ± 0.82 2.50 ± 0.88 2.50 ± 0.82 2.33 ± 1.00*     
Yawning 
PLA 0.94 ± 1.02 0.31 ± 0.58 0.42 ± 0.50 0.73 ± 0.87 0.61 ± 0.09 Treatment 0.70 
PWS 0.84 ± 0.76 0.42 ± 0.76 0.47 ± 0.61 1.00 ± 1.00 0.68 ± 0.09 Time < 0.001 
PWS150 1.15 ± 0.89 0.57 ± 0.83 0.52 ± 0.77 0.84 ± 1.11 0.78 ± 0.11 T x T 0.73 
Overall 0.98 ± 0.89 0.43 ± 0.73* 0.47 ± 0.62* 0.85 ± 0.98§†    
Alert 
PLA 2.15 ± 1.01 2.26 ± 1.09 2.31 ± 1.00 2.00 ± 1.15 2.18 ± 0.12 Treatment 0.90 
PWS 2.52 ± 0.90 2.31 ± 1.05 1.89 ± 0.87 2.26 ± 0.87 2.25 ± 0.11 Time 0.14 
PWS150 2.52 ± 0.69 2.26 ± 0.87 2.26 ± 0.73 2.10 ± 0.93 2.29 ± 0.09 T x T 0.25 
Overall 2.40 ± 0.88 2.28 ± 0.99 2.15 ± 0.88 2.12 ± 0.98*    
Tired 
/Fatigued 
PLA 1.36 ± 1.11 0.73 ± 0.80 0.84 ± 0.95 1.26 ± 0.93 1.05 ± 0.12 Treatment 0.92 
PWS 1.15 ± 1.11 0.89 ± 1.00 1.26 ± 0.87 1.15 ± 1.06 1.12 ± 0.11 Time 0.10 
PWS150 1.10 ± 0.80 0.94 ± 1.07 1.00 ± 1.10 1.05 ± 1.12 1.03 ± 0.09 T x T 0.59 
Overall 1.21 ± 1.01 0.85 ± 0.98* 1.03 ± 0.98 1.15 ± 1.03    
Content 
PLA 2.15 ± 0.95 1.94 ± 1.02 1.94 ± 1.12 1.89 ± 0.99 1.99 ± 0.12 Treatment 0.68 
PWS 2.47 ± 0.84 2.26 ± 0.87 2.21 ± 1.03 1.94 ± 1.07 2.22 ± 0.11  Time 0.07 
PWS150 2.00 ± 0.88 2.21 ± 0.91 2.15 ± 0.89 2.00 ± 0.94 2.09 ± 0.10 T x T 0.35 
Overall 2.21 ± 0.90 2.14 ± 0.93 2.10 ± 1.01 1.94 ± 0.98*    
Difficulty 
Concentrating 
PLA 1.05 ± 0.91 0.52 ± 0.77 0.63 ± 0.49 0.89 ± 0.65 0.78 ± 0.09 Treatment 0.90 
PWS 0.57 ± 0.69 0.73 ± 0.87 0.84 ± 0.50 0.68 ± 0.67 0.71 ± 0.08 Time 0.41 
PWS150 0.78 ± 0.91 0.68 ± 0.58 0.57 ± 0.76 0.78 ± 0.85 0.71 ± 0.09 T x T 0.15 
Overall 0.80 ± 0.85 0.64 ± 0.74 0.68 ± 0.60 0.78 ± 0.72    
Irritable 
PLA 0.31 ± 0.47 0.26 0.56 0.15 ± 0.37 0.21 ± 0.41 0.24 ± 0.05 Treatment 0.93 
PWS 0.36 ± 0.59 0.15 ± 0.37 0.21 ± 0.53 0.15 ± 0.37 0.22 ± 0.05 Time 0.48 
PWS150 0.26 ± 0.65 0.15 ± 0.37 0.31 ± 0.67 0.31 ± 0.58 0.26 ± 0.07 T x T 0.73 
Overall 0.31 ± 0.57 0.19 ± 0.44 0.22 ± 0.53 0.22 ± 0.46    
Heavy feelings 
in arms and legs 
PLA 0.63 ± 1.01 0.42 ± 0.60 a 0.47 ± 0.84 a,b 0.63 ± 0.95 a 0.54 ± 0.10 Treatment 0.42 
PWS 0.52 ± 0.84 0.36 ± 0.59 a 0.21 ± 0.41 0.78 ± 0.91 a 0.47 ± 0.08 Time 0.08 
PWS150 0.26 ± 0.56 0.68 ± 1.15 b,c 0.10 ± 0.31 c 0.15 ± 0.50 b,c 0.30 ± 0.08 T x T 0.02 
Overall 0.47 ± 0.82 0.49 ± 0.82 0.26 ± 0.58*§ 0.52 ± 0.84†    
Depressed Mood 
PLA 0.05 ± 0.22 0.001 ± 0.001 0.10 ± 0.31 0.001 ± 0.001 0.04 ± 0.02 Treatment 0.74 
PWS 0.10 ± 0.31 0.05 ± 0.22 0.05 ± 0.22 0.10 ± 0.45 0.08 ± 0.04 Time 0.59 
PWS150 0.05 ± 0.22 0.10 ± 0.45 0.15 ± 0.50 0.05 ± 0.22 0.09 ± 0.04 T x T 0.66 
 Overall 0.07 ± 0.25 0.05 ± 0.29 0.10 ± 0.36 0.05 ± 0.29    
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 Treatment Time (wks)    
  Day 0 Day 2 Day 4 Day 7    
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE  p-level 
Grouchy 
PLA 0.15 ± 0.37 0.10 ± 0.31 0.10 ± 0.31 0.26 ± 0.73 0.04 ± 0.02 Treatment 0.94 
PWS 0.10 ± 0.45 0.15 ± 0.68 0.15 ± 0.37 0.05 ± 0.22 0.08 ± 0.04 Time 0.69 
PWS150 0.10 ± 0.31 0.05 ± 0.22 0.21 ± 0.53 0.15 ± 0.50 0.09 ± 0.04 T x T 0.38 
Overall 0.12 ± 0.38 0.10 ± 0.45 0.15 ± 0.41 0.15 ± 0.52    
Urge to do 
work 
related 
activity 
PLA 1.78 ± 1.35 1.78 ± 1.22 1.73 ± 1.09 1.42 ± 1.01 1.68 ± 0.13 Treatment 0.89 
PWS  1.73 ± 1.14 2.05 ± 0.62 1.47 ± 0.69 1.84 ± 1.01 1.78 ± 0.10 Time 0.62 
PWS150 1.63 ± 1.16 1.52 ± 1.21 1.78 ± 1.03 1.63 ± 1.11 1.64 ± 0.13 T x T 0.13 
Overall 1.71 ± 1.20 1.78 ± 1.06 1.66 ± 0.95 1.63 ± 1.04    
Flu-like 
feelings 
PLA 0.001 ± 0.001 0.001 ± 0.001 0.05 ± 0.22 0.001 ± 0.001 0.01 ± 0.02 Treatment 0.37 
PWS 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 Time 0.32 
PWS150 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 T x T 0.37 
Overall 0.001 ± 0.001 0.001 ± 0.001 0.01 ± 0.13 0.001 ± 0.001    
Headache 
PLA 0.21 ± 0.41 0.15 ± 0.37 0.47 ± 0.90 0.31 ± 0.67 0.29 ± 0.07 Treatment 0.39 
PWS 0.15 ± 0.50 0.10 ± 0.45 0.15 ± 0.37 0.21 ± 0.53 0.16 ± 0.05 Time 0.16 
PWS150 0.21 ± 0.53 0.001 ± 0.001 0.21 ± 0.63 0.21 ± 0.53 0.16 ± 0.06 T x T 0.81 
Overall 0.19 ± 0.47 0.08 ± 0.34 0.28 ± 0.67§ 0.24 ± 0.57§    
Talkative 
PLA 1.31 ± 1.29 1.36 ± 1.38 1.52 ± 1.30 1.26 ± 1.14 1.37 ± 0.14 Treatment 0.98 
PWS 1.31 ± 1.20 1.50 ± 1.47 1.05 ± 1.12 1.42 ± 1.21 1.32 ± 0.14 Time 0.60 
PWS150 1.42 ± 1.07 1.37 ± 1.42 1.47 ± 1.34 1.05 ± 1.07 1.34 ± 0.14 T x T 0.25 
Overall 1.35 ± 1.17 1.42 ± 1.32 1.35 ± 1.26 1.24 ± 1.13    
Sluggish 
PLA 0.57 ± 0.69 0.42 ± 0.50 0.31 ± 0.58 0.52 ± 0.77 0.46 ± 0.07 Treatment 0.60 
PWS 0.42 ± 0.69 0.31 ± 0.67 0.21 ± 0.41 0.31 ± 0.47 0.32 ± 0.07 Time 0.10 
PWS150 0.42 ± 0.60 0.36 ± 0.59 0.26 ± 0.56 0.52 ± 0.69 0.39 ± 0.07 T x T 0.96 
Overall 0.47 ± 0.65 0.36 ± 0.58 0.26 ± 0.51* 0.45 ± 0.65     
Upset 
stomach 
 
PLA 0.10 ± 0.31 0.10 ± 0.31 0.21 ± 0.71 0.21 ± 0.41 0.16 ± 0.05 Treatment 0.52 
PWS 0.26 ± 0.73 0.001 ± 0.001 0.15 ± 0.50 0.15 ± 0.50 0.14 ± 0.06 Time 0.25 
PWS150 0.10 ± 0.31 0.001 ± 0.001 0.05 ± 0.22 0.10 ± 0.31 0.07 ± 0.03 T x T 0.79 
Overall 0.15 ± 0.49 0.03 ± 0.18 0.14 ± 0.51 0.15 ± 0.41§    
Clearheaded 
 
PLA 1.84 ± 1.16 1.63 ± 1.11 1.63 ± 1.11 1.47 ± 1.02 1.64 ± 0.13 Treatment 0.95 
PWS 1.73 ± 0.80 1.84 ± 1.06 1.73 ± 1.24 1.63 ± 1.11 1.74 ± 0.12 Time 0.08 
PWS150 1.68 ± 1.15 1.89 ± 1.28 1.68 ± 1.10 1.42 ± 1.07 1.67 ± 0.13 T x T 0.76 
Overall 1.75 ± 1.03 1.78 ± 1.14 1.68 ± 1.13 1.50 ± 1.05§    
Desire to 
socialize 
PLA 1.57 ± 1.26 1.73 ± 1.28 1.63 ± 1.25 1.26 ± 1.04 1.55 ± 0.14 Treatment 0.97 
PWS 1.47 ± 1.12 1.68 ± 1.33 1.31 ± 1.36 1.47 ± 1.21 1.50 ± 0.13 Time 0.03 
PWS150 1.47 ± 1.17 1.57 ± 1.07 1.63 ± 1.34 1.21 ± 1.18 1.47 ± 0.14 T x T 0.61 
Overall 1.50 ± 1.16 1.66 ± 1.21 1.54 ± 1.19 1.31 ± 1.13§    
Energetic 
PLA 1.73 ± 1.14 1.89 ± 1.14 1.89 ± 1.24 1.31 ± 1.00 1.71 ± 0.13 Treatment 0.99 
PWS 1.78 ± 1.18 1.89 ± 1.19 1.47 ± 1.02 1.63 ± 1.16 1.70 ± 0.13 Time 0.06 
PWS150 1.78 ± 0.97 1.63 ± 1.01 1.94 ± 1.26 1.47 ± 0.90 1.71 ± 0.12 T x T 0.24 
Overall 1.77 ± 1.08 1.80 ± 1.10 1.77 ± 1.18 1.47 ± 1.01*
§     
 87 
 
 
Table 4.18 Continued 
 
 
 Treatment Time (wks)    
  Day 0 Day 2 Day 4 Day 7    
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE  p-level 
Nausea/ 
vomiting 
PLA 0.05 ± 0.22 0.001 ± 0.001 0.21 ± 0.71 0.10 ± 0.31 0.04 ± 0.02 Treatment 0.50 
PWS 0.15 ± 0.37 0.001 ± 0.001 0.001 ± 0.001 0.10 ± 0.31 0.07 ± 0.03 Time 0.84 
PWS150 0.001 ± 0.001 0.10 ± 0.45 0.001 ± 0.001 0.001 ± 0.001 0.03 ± 0.05 T x T 0.11 
Overall 0.07 ± 0.25 0.03 ± 0.26 0.07 ± 0.41 0.07 ± 0.25    
Muscle 
pain/stiffness
/aches 
PLA 0.57 ± 0.83 0.63 ± 0.95 0.42 ± 0.60 0.47 ± 0.84 0.53 ± 0.09 Treatment 0.73 
PWS 0.57 ± 0.76 0.89 ± 0.80 0.42 ± 0.60 0.68 ± 0.88 0.64 ± 0.09 Time 0.06 
PWS150 0.57 ± 0.69 0.68 ± 1.10 0.42 ± 0.76 0.31 ± 0.82 0.50 ± 0.10 T x T 0.82 
Overall 0.57 ± 0.75 0.73 ± 0.95 0.42 ± 0.65§ 0.49 ± 0.84    
Discouraged 
PLA 0.001 ± 0.001 0.10 ± 0.31 0.10 ± 0.31 0.10 ± 0.31 0.08 ± 0.03 Treatment 0.80 
PWS 0.05 ± 0.22 0.001 ± 0.001 0.10 ± 0.31 0.15 ± 0.37 0.08 ± 0.03 Time 0.12 
PWS150 0.05 ± 0.22 0.10 ± 0.31 0.15 ± 0.50 0.15 ± 0.37 0.12 ± 0.04 T x T 0.82 
Overall 0.03 ± 0.18 0.07 ± 0.25 0.12 ± 0.38 0.14 ± .35*    
Dizziness 
PLA 0.26 ± 0.73 0.001 ± 0.001 0.05 ± 0.22 0.10 ± 0.31 0.11 ± 0.05 Treatment 0.91 
PWS 0.15 ± 0.37 0.05 ± 0.22 0.001 ± 0.001 0.10 ± 0.45 0.08 ± 0.04 Time 0.03 
PWS150 0.15 ± 0.37 0.001 ± 0.001 0.15 ± 0.50 0.001 ± 0.001 0.08 ± 0.04 T x T 0.46 
Overall 0.19 ± 0.51 0.01 ± 0.13* 0.07 ± 0.31 0.07 ± 0.31    
Desire to 
work out 
PLA 2.36 ± 1.21 2.26 ± 1.24 1.94 ± 1.31 1.78 ± 1.13 2.09 ± 0.14 Treatment 0.93 
PWS 2.21 ± 1.27 2.10 ± 1.04 1.78 ± 1.27 2.10 ± 1.48 2.05 ± 0.14 Time 0.07 
PWS150 2.10 ± 0.99 2.05 ± 1.07 1.94 ± 1.43 1.78 1.27 1.97 ± 0.14 T x T 0.77 
Overall 2.22 ± 1.14 2.14 ±1.10 1.89 ± 1.31 1.89 ± 1.29*    
Queasy 
PLA 0.05 ± 0.22 0.001 ± 0.001 0.26 ± 0.65 0.001 ± 0.001 0.08 ± 0.04 Treatment 0.96 
PWS 0.10 ± 0.31 0.001 ± 0.001 0.15 ± 0.50 0.10 ± 0.31 0.09 ± 0.04 Time 0.053 
PWS150 0.05 ± 0.22 0.10 ± 0.45 0.21 ± 0.53 0.001 ± 0.001 0.09 ± 0.04 T x T 0.70 
Overall 0.07 ± 0.25 0.03 ± 0.26 0.21 ± 0.55§ 0.03 ± 0.18     
Nauseous 
PLA 0.05 ± 0.22 0.001 ± 0.001 0.15 ± 0.50 0.001 ± 0.001 0.05 ± 0.03 Treatment 0.84 
PWS 0.15 ± 0.37 0.001 ± 0.001 0.001 ± 0.001 0.10 ± 0.31 0.07 ± 0.03 Time 0.62 
PWS150 0.05 ± 0.22 0.10 ± 0.45 0.001 ± 0.001 0.001 ± 0.001 0.04 ± 0.03 T x T 0.09 
Overall 0.08 ± 0.28 0.03 ± 0.26 0.05 ± 0.29 0.03 ± 0.18    
 PLA 0.001 ± 0.001 0.001 ± 0.001 0.05 ± 0.22 0.05 ± 0.22 0.03 ± 0.02 Treatment 0.13 
Vomiting PWS 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 Time 0.50 
 PWS150 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 0.001 ± 0.001 T x T 0.60 
 Overall 0.001 ± 0.001 0.001 ± 0.001 0.01 ± 0.13 0.01 ± 0.13    
Headachy 
PLA 0.21 ± 0.53 0.15 ± 0.37  0.42 ± 0.90 0.26 ± 0.56 0.26 ± 0.07 Treatment 0.63 
PWS 0.26 ± 0.45 0.10 ± 0.31 0.15 ± 0.37 0.15 ± 0.50 0.17 ± 0.05 Time 0.14 
PWS150 0.21 ± 0.53 0.001 ± 0.001  0.15 ± 0.50 0.26 ± 0.56 0.16 ± 0.05 T x T 0.52 
Overall 0.22 ± 0.50 0.08 ± 0.28* 0.24 ± 0.63 0.22 ± 0.53§    
Anxious 
PLA 0.73 ± 1.19 0.21 ± 0.71 0.31 ± 0.94 0.42 ± 0.96 0.42 ± 0.11 Treatment 0.99 
PWS 0.47 ± 1.20 0.36 ± 0.95 0.36 ± 0.95 0.47 ± 0.84 0.42 ± 0.11 Time 0.42 
PWS150 0.21 ± 0.53 0.36 ± 0.59 0.57 ± 1.07 0.47 ± 0.84 0.41 ± 0.09 T x T 0.11 
Overall 0.47 ± 1.00 0.31 ± 0.75 0.42 ± 0.98 0.45 ± 0.86    
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 Treatment Time (wks)    
  Day 0 Day 2 Day 4 Day 7    
  Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SE  p-level 
Nervous 
PLA 0.10 ± 0.31 0.05 ± 0.22 0.10 ± 0.31 0.15 ± 0.50 0.11 ± 0.04 Treatment 0.87 
PWS 0.10 ± 0.45 0.05 ± 0.22 0.21 ± 0.71 0.10 ± 0.31 0.12 ± 0.05 Time 0.70 
PWS150 0.10 ± 0.31 0.10 ± 0.31 0.10 ± 0.45 0.001 ± 0.001 0.08 ± 0.04 T x T 0.78 
Overall 0.10 ± 0.36 0.07 ± 0.25 0.14 ± 0.51 0.08 ± 0.34    
Jittery 
PLA 0.78 ± 1.18 0.26 ± 0.65 0.15 ± 0.50 0.21 ± 0.41 0.36 ± 0.09 Treatment 0.79 
PWS 0.63 ± 1.21 0.05 ± 0.22 0.001 ± 0.001 0.47 ± 1.02 0.29 ± 0.10 Time <0.001 
PWS150 0.63 ± 1.30 0.10 ± 0.31 0.05 ± 0.22 0.21 ± 0.53 0.25 ± 0.09 T x T 0.68 
Overall 0.68 ± 1.21 0.14 ± 0.44* 0.07 ± 0.31* 0.29 ± 0.70*     
Craving 
for 
caffeine 
PLA 0.36 ± 1.01 0.47 ± 1.07 0.68 ± 1.20 0.63 ± 1.16 0.54 ± 0.13 Treatment 0.90 
PWS 0.31 ± 0.74 0.47 ± 0.90 0.52 ± 0.96 0.52 ± 0.96 0.46 ± 0.10 Time 0.13 
PWS150 0.63 ± 1.21 0.57 ± 1.16 0.63 ± 1.11 0.57 ± 1.12 0.61 ± 0.13 T x T 0.60 
Overall 0.43 ± 1.00 0.50 ± 1.03 0.61 ± 1.08* 0.57 ± 1.06    
Craving 
for coffee 
PLA 0.36 ± 0.95 0.36 ± 0.95 0.31 ± 1.00 0.42 ± 1.07 0.37 ± 0.11 Treatment 0.82 
PWS 0.15 ± 0.50 0.42 ± 0.83 0.42 ± 0.90 0.52 ± 0.96 0.38 ± 0.09 Time 0.11 
PWS150 0.52 ± 1.07 0.57 ± 1.16 0.47 ± 1.02 0.57 ± 1.16 0.54 ± 0.12 T x T 0.32 
Overall 0.35 ± 0.87 0.45 ± 0.98 0.40 ± 0.96 0.50 ± 1.05    
Values are means ± standard deviations. Caffeine questionnaire data were analyzed by MANOVA with repeated measures. 
Greenhouse-Geisser treatment (T), time (T), and treatment x time (T x T) interaction p-levels are reported with univariate treatment 
p-levels.  MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.99), time (p < 0.001), and treatment x time (p = 
0.33). a denotes a significant difference from PWS150. b denotes a significant difference from PWS. c denotes a significant 
difference from PLA. * represents p < 0.05 difference from Day 0. § represents p < 0.05 difference from Day 2.† represents p < 
0.05 difference from Day 4.  
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
Discussion 
 A variety of PWS’s which contain several ingredients are broadly marketed to 
athletes and recreational exercisers with claims of improved performance or exercise 
effectiveness. The primary aim of this study was to examine a PWS at two doses on 
performance readiness, exercise performance and potential alterations in thermogenic 
and hemodynamic function and blood chemistries denoting hepatorenal and muscle 
enzyme function in healthy individuals. Furthermore, this study sought out to determine 
whether PWS150 at ~150% the PWS dose was more efficacious than the PWS to 
improve readiness to perform, cognitive function, and exercise performance. Our study 
adds to the known literature on PWS’ by examining measured and perceived readiness to 
perform exercise. This latter point is important as number of multi-ingredient PWS’ are 
available in the market, few studies attempt to match “exercise preparedness” and 
exercise performance. 
In the current study, we observed significant increases in readiness, denoted by 
improved cognitive function examined by the Stroop Word-Color Test. Overall, we 
found that the PWS150 significantly improved all Stroop tested domains, as well as the 
sum of all scores combined. The changes denoted for the PLA and PWS treatments are 
less clear as the PLA demonstrated an improvement in two domains, but not the 
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summated score, while the PWS showed improvement in one domain, yet, demonstrated 
significant improvement for the summated score. Given the results of the Stroop Test we 
accept our hypothesis that the PWS150 formula improved performance readiness via 
improved cognitive function. While significant improvements were observed in PWS150 
compared to PWS and PLA, other researchers reported similar improvements. Hoffman 
et al. [217] examined the acute effect of a high energy drink (120ml) containing caffeine, 
β-alanine, vitamin C, and herbal compounds on reaction time, subjective feelings of 
energy, fatigue, alertness and focus. Subjective feelings of energy (3.5 ± 0.5 vs. 3.1 ± 
0.5) and focus (3.8 ± 0.5 vs. 3.3 ± 0.7) were significantly higher during PWS 
supplementation compared to PLA, respectively. In addition, the authors observed a 
tendency towards an increase in average alertness (p = 0.06) in PWS compared to PLA. 
Our results in cognitive function are also in agreement with Hogervorst et al. [10] that 
revealed an additive effect of a dietary supplement on the activating and cognition 
enhancing effects of exercise. Caffeine supplementation prior to (150mg/L) and during 
(6ml/kg) exercise improved memory, concentration, and complex reaction times in 
athletes after exercise. Conversely, Judelson et al. [218] did not observe any effects of 3 
or 6mg/kg/day of caffeine supplementation for 5 days on cognitive performance, 
psychomotor skills, and mood. 
In the current study, we did not observe a significant increase in readiness to 
perform using VAS. Therefore, we reject the hypothesis that PWS is capable of 
enhancing perceptions of readiness to perform. Our results in readiness to perform are in 
agreement with Gonzalez et al. [219] who reported no significant change in VAS 
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determined feeling of energy when ingesting a PWS containing 2.1g of taurine, 
glucuronolactone and caffeine, 7.9g of leucine, isoleucine, valine, arginine and 
glutamine, 5g of di-creatine citrate, and 2.5g of β-alanine. Similarly, Joy et al. [220] 
reported that no differences were present in psychometric scores of perceived recovery, 
soreness, or readiness to train by consuming 48g of rice or whey protein isolate on 
training days, 3 days/week, for eight weeks as a part of a daily undulating periodized 
resistance-training program. On the contrary, Hoffman et al. [217] observed a 
significantly greater feeling of energy and focus compared to PLA after ingesting a 
supplement containing various amino acids. Research by Kedia et al. [221] indicated 
significant improvements in VAS scores for energy (p < 0.024) and concentration (p < 
0.041) along with consistently higher levels of focus accompanied by less fatigue when a 
blend of PWS (5.3g/day) containing caffeine anhydrous, Cr monohydrate, vitamin C, 
and B vitamins was consumed. 
 In the current study, we did not see any significant changes in REE components 
including O2, CO2, and RER. Based on the literature, caffeine levels has shown to 
peak 30-120 min after oral intake [222]. We conducted the post-ingestion REE 
measurement immediately after ingesting the assigned supplement. That may explain 
why we did not observe significant thermogenic changes after supplement ingestion. 
Judice and colleagues [223] investigated the impact of a moderate dose of caffeine (5 
mg/kg/day) on REE in a 4-day period and the acute effects on REE in physically active 
males. The findings revealed no acute or long-term effects of caffeine on REE among 
participants. Conversely, some other studies have indicated that ingesting a caffeine-
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containing supplement increases REE components. For example, Astrup et al. [224] 
showed that the highest and the lowest caffeine dose (400 and 100mg) raised REE above 
PLA but not the intermediate dose (200 mg of caffeine). Ryan et al. [225] reported that 
ingestion of a thermogenic supplement containing caffeine, capsaicin, bioperine, and 
niacin increased energy expenditure and oxygen uptake values. Miles-Chan et al. [226] 
reported that consumption of a sugar free energy drink containing 120 mg of caffeine 
increased REE by about 4% and that the changes observed were due to the caffeine in 
the drinks rather than other nutrients (i.e., taurine and glucuronolactone).    
In the present study, we observed a significant increase in post-bench press SBP 
in PWS treatment ~1-hr after ingesting the supplement and a significant decrease in 
PLA, while observing no significant differences in PWS150. The increase in SBP in 
PWS and the decrease in PLA were well-within normal resting BP changes (180-200 
max). Since no changes in HR, SBP or DBP were observed after leg press and Wingate 
tests, the changes were most likely transient and unrelated to supplementation. In 
addition, no participant had hypotensive response (SBP < 90mmHG, DBP < 60mmHG) 
to either dose of PWS studied. Therefore, we reject the hypothesis that two formulae are 
capable of changing HR and BP responses. Some studies have shown the effects of 
dietary supplements on HR and BP [227-229]. The elevation of HR and BP following an 
ingestion of caffeine-containing supplements seems plausible in light of several related 
physiological mechanisms. Caffeine affects neurotransmission at both central and 
peripheral sites, primarily due to its antagonistic action at adenosine receptors [230]. 
Bloomer et al. [231] reported that acute geranamine (50mg) supplementation resulted in 
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an increase in SBP (~20%) and DBP (~17%), without an increase in HR. The largest 
increase was observed at 60 min post-ingestion. On the other hand, Dong et al. [228] 
observed that L-arginine intervention significantly lowered SBP by 5.4 mmHG (95% CI 
−8.5 to −2.3, p = 0.001) and DBP by 2.6 mmHG (95% CI −3.7 to −1.5, p = 0.001), 
compared to PLA. Our findings for HR are in agreement with Larsen et al. [227] who 
reported no significant change in HR after nitrate supplementation (6.2mg/kg/day) for 
three days. Similarly, Galvan et al. [232] did not observe any significant changes for HR, 
SBP, and DBP in resistance-trained males after acute ingestion of either Cr monohydrate 
or Cr nitrate (12g/day). Daniels et al. [86] found out that DBP and HR were unaffected 
by acute caffeine ingestion (6mg/kg) during dynamic leg exercise. Conversely, Larsen et 
al. [233] and Webb et al. [121] both observed a decrease in DBP of 3.7 and 8.1 mmHG 
after ~430mg (70 kg body weight at 6.2mg/kg/day-1) and 1,400mg nitrate 
supplementation, respectively.  
 We observed no significant alterations in whole blood makers and general health 
markers. However, plasma Cr concentrations significantly increased over time among all 
treatments (p = 0.02). In addition, no significant treatment x time interactions were 
observed for any blood lipid marker. Therefore, we accept our hypothesis that two 
formulae do not adversely alter clinical markers within the context of study over a 7-day 
period. Our results are in agreement with Galvan et al. [232] that did not find significant 
changes in TC, HDL, TC/HDL ratio, LDL, and TG after acute and chronic dose-
dependent Cr nitrate supplementation and exercise performance. Earnest et al. [234] also 
observed no significant changes in HDL after the Cr supplementation period.  
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 In the present study, there was no significant difference over time in total lifting 
volume, peak power, average power, and average velocity during the bench press test 
after 7 days of supplementation. Similar results in bench press performance were 
observed by Green et al. [84]. Physically active men and women performed three sets of 
bench press to failure at 80% of 1RM with a dosage of 6mg/kg of caffeine. No 
significant difference was shown for bench press between caffeine and PLA treatments. 
Others have also reported similar results in bench press power. Astorino et al. [35] had 
participants perform one set of repetitions to failure for bench press at 60% 1RM with 
6mg/kg of caffeine. No significant difference was found for bench press with caffeine 
compared to PLA. Martinez et al. [235] did not also observe the significant acute effects 
of a caffeine-containing PWS in upper body power or strength. On the contrary, Forbes 
et al. [236] observed the significant acute effect of a caffeine-containing energy drink 
(2mg/kg) on upper body muscle endurance. In addition, Goldstein et al. [237] reported 
that acute caffeine ingestion (6mg/kg-1) significantly increased 1RM in the bench press 
but not bench press repetitions to failure at 60% 1RM in resistance trained women.    
 We observed no significant difference among treatments in leg press lifting 
volume. Similarly, Outlaw et al. [238] found no significant treatment × time interaction 
in leg press performance following eight days of supplementation with either a PWS 
containing Cr monohydrate-β-alanine blend (8.4g), BCAAs (4.8g), and caffeine (275mg) 
or PLA in 30 min before a resistance training workout and after completing baseline 
testing. Walter et al. [239] indicated that the acute ingestion of a supplement containing 
caffeine (200mg), capsaicin (33.3mg), bioperine (5mg), and niacin (20mg) did not alter 
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leg press performance. Conversely, Green et al. [84] reported that caffeine consumption 
(6mg/kg) resulted in a greater number of repetitions during leg press to failure at 10 
repetition maximum.   
We did not observe significant Treatment x Time interaction among treatments in 
overall peak power, mean power, total work, rate of fatigue, and minimum power during 
anaerobic sprint capacity test; however, we found a significant change in Wingate mean 
power at day 7 only in PWS150. In addition, some percent change improvements were 
seen in anaerobic total work and minimum power. Similar improvements were reported 
by others. Jagim et al. [240], reported a 3% improvement in total work during a 30-sec 
cycle ergometer test after 28 days of Cr and two doses of a buffered form of Cr 
supplementation. Ahmun et al. [241] observed a 4.9%, 4.4%, and 0.5% increase in peak 
power, minimum power, and fatigue index respectively, on a cycle ergometer after acute 
Cr supplementation. Koçak and Karli [242] revealed that the average and peak power 
mean scores obtained from anaerobic sprint post-test (8.12 W/kg and 10.5 W/kg) were 
significantly higher than pretest (7.23 W/kg and 8.99 W/kg) for the Cr supplement 
group. On the contrary, Williams et al. [243] found that 300mg of ephedra and caffeine 
did not positively enhance Wingate test performance. Research by Greer et al. [244] 
reported that ingestion of caffeine (6mg/kg-1) did not significantly enhance performance 
during 4 repeated Wingate tests. 
 The lack of difference in strength and most anaerobic sprint capacity variables 
can be explained by several reasons. Basically, low-doses of the supplement may explain 
the lack of difference between the two doses of PWS. For example, the Cr nitrate doses 
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contained in PWS and PWS150 supplements were 2.0g and 3.0g respectively. These 
doses for Cr are lower than the typical 5-7g/day which has been demonstrated by several 
studies to be effective at inducing ergogenic aids in conjunction with resistance training 
[93, 245, 246]. In the Willoughby and Rosene study [246], 6g/day-1 of Cr for 12 weeks 
with performing resistance training trice weekly resulted in preferential increases in 
muscle strength and mass. A normal intra-personal variation in performance could have 
also influence the exercise performance before and after the supplementation period. 
Another reason could be the differences in length of time of the current protocol and 
other studies like that of Lowery et al. [94] which may at least partially explain our 
insignificant exercise performance results. In that study, the length of training was eight 
weeks and they found significant group-by-time interaction in which the PWS 
supplementation resulted in a significant increase in strength of the bench press (18.4% 
vs. 9.6%) compared to PLA. 
Summary and Conclusion  
A strength of our study is that we used a cross-over design that was adjusted for 
gender. We believe that this latter point is important as it is not untypical for similar trial 
to use mixed gender cohorts without such adjustments, assuming that men and women 
will respond similarly to supplementation schema. We also recruited participants with at 
least six months of strength training experience, inclusive of some of the performance 
parameters we examined, thus minimizing training and familiarity effects. A potential 
limitation was the length of the study. In a recent chronic study from our group (Jung et 
al., in press), some improvements were observed in cognitive function and 1RM strength 
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performance. Therefore, conducting more chronic trials would likely provide a more 
robust assessment of the potential for alterations in blood chemistries, improved 
performance readiness or exercise performance. Thus, while the results of our study 
demonstrated an increase in cognitive performance using a higher dosed formula (i.e. 
PWS150) unmatched by perceived readiness, exercise performance, hematology or 
adverse alterations in pre- and post-exercise hemodynamic responses to exercise. 
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